7th
March 2024
2023 Full Year
Results
A challenging trading
environment in 2023; well positioned for a return to growth in
2024
Twelve
months ended 31st December
Statutory (£m/p)
|
2023
|
2022
|
Reported
|
Revenue+
|
1,682.6
|
1,610.6
|
+4%
|
Operating profit
|
284.4
|
318.8
|
-11%
|
Operating profit margin
|
16.9%
|
19.8%
|
-290bps
|
Profit before taxation
|
244.5
|
308.1
|
-21%
|
Basic earnings per
share
|
249.5
|
305.1
|
-18%
|
Dividend per share
|
160.0
|
152.0
|
+5%
|
Adjusted (£m/p)
|
2023
|
2022
|
Reported
|
Organic*
|
Revenue+
|
1,682.6
|
1,610.6
|
+4%
|
-1%
|
Adjusted operating
profit
|
349.1
|
380.2
|
-8%
|
-12%
|
Adjusted operating profit
margin
|
20.7%
|
23.6%
|
-290bps
|
-270bps
|
Adjusted profit before
taxation
|
309.2
|
370.6
|
-17%
|
|
Adjusted basic earnings per
share
|
312.4
|
377.2
|
-17%
|
|
Adjusted cash
conversion
|
81%
|
57%
|
|
|
·
Revenues up 4% reflecting full-year contribution
from acquisitions; down 1% organically
·
Organic revenue growth in STS++ (8%)
and ETS++ (2%) outperformed global IP+++ of
0.3%
·
Watson-Marlow organic revenue declined by 19% due
to weak Biopharm** demand
·
Group organic revenue growth in H1 was offset by
a decline in H2, driven by weakening IP outlook
·
Early restructuring actions and cost containment
partially mitigated margin impact, particularly in H2
·
Adjusted operating profit margin reflects adverse
mix impact of lower volumes in higher margin businesses
·
Statutory operating profit and margin reflect
impact of restructuring and impairment costs
·
Strong recovery in adjusted cash conversion;
above guidance due to phasing of large capital projects
·
Total dividend of 160.0 pence per share,
maintaining 56 year track record
·
Return to organic sales growth and adjusted
operating profit margin progress expected in 2024
Nimesh Patel, Group Chief Executive Officer, commenting on
the results said:
"Our financial results in 2023 were impacted by a more
challenging trading environment than we had anticipated at the
start of the year, with a number of external headwinds to our
highest margin businesses. An early focus on restructuring to
right-size capacity, together with cost containment actions,
supported our adjusted operating profit margin. We are well
positioned to return to revenue and profit growth in
2024.
It is a privilege to lead Spirax Group, working alongside
outstanding people to continue building on the strengths of our
unique business model. We have a long track record of
navigating volatile macroeconomic conditions to deliver growth
ahead of industrial production. Our decision to maintain
revenue investment in critical strategic initiatives, such as
further developing our digital and decarbonisation capabilities,
will support the delivery of compounding growth at attractive
margins for many years to come."
+ 'Sales' is used interchangeably with 'revenue' when
describing the financial performance of the business
++ 'STS': Steam Thermal Solutions; 'ETS': Electric Thermal
Solutions
+++ 'IP': Industrial Production growth
* Organic measures are at constant
currency and exclude contributions from acquisitions and disposals
(with our Russian Operating Companies treated as disposals from the
date at which the Group suspended all trading with and within
Russia)
** 'Biopharm' refers to
Watson-Marlow sales to the Pharmaceutical & Biotechnology
sector
See Appendix to the Financial
Statements for an explanation of alternative performance
measures.
For further information, please contact:
Phil Scott, Interim Chief
Financial
Officer:
+44 (0) 1242 535234
Mal Patel, Head of Investor
Relations:
+44 (0) 1242 535234
Media
Martin Robinson, Teneo:
+44 (0) 20 7260 2700, spiraxgroup@teneo.com
Audio
webcast
The results presentation will be available as a live webcast
at 9.15 am on the Company's website at www.spiraxgroup.com or via
the following link:
https://edge.media-server.com/mmc/p/g9a8ou9i/
A recording will be made available on the website shortly
after the meeting.
About Spirax Group
Spirax Group (formerly
Spirax-Sarco Engineering) is positioned to play a critical role in
enabling the industrial transition to net zero, aligned to our
Purpose to create sustainable value for all our stakeholders as we
engineer a more efficient, safer and sustainable world. We
put solving customers' problems at the heart of our 'total
solutions' approach. Our global thermal energy and fluid technology
solutions improve operating efficiency and safety in our customers'
critical industrial processes. Our recently launched new-to-world
decarbonisation* solutions use proprietary technologies to
electrify boilers, for the raising of steam, as well as the
electrification of other critical industrial process heating
applications.
Spirax Group comprises three
strong and aligned Businesses: Steam Thermal
Solutions helps customers control
and manage steam within their mission critical industrial
applications, such as cleaning, sterilising, cooking and
heating. We are helping to put food safely on the world's
tables and keeping our hospitals running. Electric Thermal
Solutions has proprietary
technologies that deliver electrification solutions at scale in
industrial settings, including for the raising of steam, supporting
our customers to achieve their net zero goals. We also deliver
freeze protection and defrost solutions critical to aviation and
space industries and ensure thermal uniformity in Semiconductor
chip manufacturing to power the critical electronic systems we rely
on. Watson‐Marlow Fluid Technology Solutions
is engineering vital fluid technology solutions
that optimise the efficient use of resources and support
advancements in global health, such as lifesaving vaccines and gene
therapies.
Spirax Group is headquartered in
Cheltenham (UK). We have 37 strategically located manufacturing
plants around the world and are committed to creating a safe and
inclusive working culture for our 10,000 colleagues, operating in
66 countries and serving 110,000 customers
globally.
The Company's shares have been
listed on the London Stock Exchange since 1959 (symbol: SPX) and we
are a constituent of the FTSE 100 and the FTSE4Good
Indexes.
* Eliminates scope 1 and 2
greenhouse gas emissions when connected to a green electricity
source.
Further information can be found
at spiraxgroup.com
RNS filter: Inside information prior to release
LEI 213800WFVZQMHOZP2W17
SUMMARY FINANCIALS
12 months to 31st December
|
2023
|
2022
|
y-o-y
change
|
|
£m
|
£m
|
Organic*
|
Reported
|
SUMMARY FINANCIALS
|
|
|
|
|
|
|
|
|
|
Steam Thermal Solutions
(STS)
|
910.1
|
866.0
|
+8%
|
+5%
|
Electric Thermal Solutions
(ETS)
|
378.5
|
256.1
|
+2%
|
+48%
|
Watson-Marlow
|
394.0
|
488.5
|
-19%
|
-19%
|
Group Revenue
|
1,682.6
|
1,610.6
|
-1%
|
+4%
|
|
|
|
|
|
STS
|
205.2
|
196.2
|
|
+5%
|
ETS
|
25.8
|
7.3
|
|
+253%
|
Watson-Marlow
|
81.2
|
154.4
|
|
-47%
|
Corporate
|
(27.8)
|
(39.1)
|
|
-29%
|
Group Statutory Operating Profit
|
284.4
|
318.8
|
|
-11%
|
|
|
|
|
|
STS
|
22.5%
|
22.7%
|
|
-20bps
|
ETS
|
6.8%
|
2.9%
|
|
+390bps
|
Watson-Marlow
|
20.6%
|
31.6%
|
|
-1,100bps
|
Group Statutory Operating Profit Margin
|
16.9%
|
19.8%
|
|
-290bps
|
|
|
|
|
|
STS
|
224.0
|
206.1
|
+15%
|
+9%
|
ETS
|
59.2
|
39.9
|
-4%
|
+48%
|
Watson-Marlow
|
93.7
|
160.0
|
-43%
|
-41%
|
Corporate
|
(27.8)
|
(25.8)
|
+8%
|
+8%
|
Group Adjusted Operating Profit*
|
349.1
|
380.2
|
-12%
|
-8%
|
|
|
|
|
|
STS
|
24.6%
|
23.8%
|
+140bps
|
+80bps
|
ETS
|
15.6%
|
15.6%
|
-90bps
|
+0bps
|
Watson-Marlow
|
23.8%
|
32.8%
|
-1,030bps
|
-900bps
|
Group Adjusted Operating Profit Margin*
|
20.7%
|
23.6%
|
-270bps
|
-290bps
|
|
|
|
|
|
Cashflow
|
|
|
|
|
Statutory cash from
operations
|
298.6
|
241.1
|
|
+24%
|
Adjusted cash from
operations*
|
281.7
|
214.9
|
|
+31%
|
Adjusted cash
conversion*
|
81%
|
57%
|
|
+2400bps
|
Net debt*
|
666.7
|
690.4
|
|
-3%
|
Leverage (net debt to
EBITDA)*
|
1.7x
|
1.7x
|
|
|
* All adjusting
measures are reconciled to their nearest statutory equivalent in
the Appendix to the Financial Statements.
GROUP CHIEF EXECUTIVE OFFICER'S
REVIEW
Introduction
I took over as Group Chief
Executive Officer of Spirax-Sarco Engineering (now rebranded Spirax
Group) on 16th January 2024, following Nick Anderson's
retirement. Over the past ten years, under Nick's leadership,
we have established strong positions in what are now three very
significant Businesses with exciting future potential. I am
grateful to Nick for bringing me into the Group and for laying the
strong foundations that will support our journey in the years to
come. I feel privileged to be leading Spirax Group and would
like to thank the Board and my Group Executive Committee (GEC)
colleagues for their support through this leadership
transition.
Summary of 2023 performance
The macroeconomic environment was
materially weaker in 2023. Global industrial production
growth (IP) was 0.3% compared to 2.1% in 2022, with lower growth in
all regions. IP was materially lower than the 1.4% that had been
forecast at the beginning of the year with downward revisions to
second half growth particularly marked in North America and
China. The Group was also impacted by external demand
challenges in our Biopharm and Semiconductor (Semicon1)
sectors (which accounted for approximately 16% and 4% of 2022
proforma2 sales respectively), due to customer
destocking.
Against this backdrop, the Group's
financial performance in 2023 was in line with the expectations we
set out in our November 2023 trading update.
We saw strong demand during the
first half in STS and the industrial process focused Divisions of
ETS (Chromalox and Vulcanic). However, demand from industrial
equipment customers of ETS was lower, particularly in Semicon,
impacting Durex Industries and to a lesser extent, Thermocoax.
Demand in Watson-Marlow was also weak, driven by Biopharm
customers destocking post the COVID pandemic. As a result,
Group sales grew organically by 2% in the first half, reflecting
strong growth in STS (15%) and ETS (7%) offset by a decline in
Watson-Marlow (21%).
In the second half, the
macroeconomic backdrop weakened for STS and the industrial process
focused Divisions of ETS, while Biopharm demand remained subdued
and Semicon demand was lower than in the first half. Group
sales declined organically by 4% in the second half, reflecting
slower growth in STS (2%) and declines in ETS (2%) and
Watson-Marlow (17%).
Group revenues in 2023 declined by
1% organically compared to 2022 (down 1.5% compared to proforma
2022 sales), to £1,682.6 million. Sales benefited from a full
year's contribution from the Vulcanic and Durex Industries
acquisitions but were also impacted by a currency headwind of 2%
and a small adverse impact from the disposal of our Russian
operations in 2022. Lower sales in our highest margin businesses impacted full year adjusted
operating profit, which was down 12% organically to £349.1 million,
with full year adjusted operating profit margin down by 270 bps,
organically, to 20.7%. This outcome reflects our strong
pricing discipline, which helped to partially mitigate the impact
of lower volumes and adverse sales mix on our margin, even as cost
inflationary pressures eased.
Recognising the challenging
trading environment, we took early action across all three
Businesses to appropriately right-size capacity and overhead
support costs as well as implementing temporary cost containment
actions and reducing variable compensation across the Group.
As a result of these actions, Group adjusted operating profit in
the second half grew by 3% compared to the first half, despite
sales being lower. We protected our ability to respond to an
anticipated recovery in demand by continuing to invest in a number
of strategic initiatives that underpin the Group's long-term
growth. I am grateful to my colleagues around the world for
their commitment, expertise and efforts, as well as their continued
focus on delivery for all stakeholders, during these more
challenging times.
The Board has declared a final
dividend of 114.0 pence (2022: 109.5 pence) per ordinary share,
bringing the total dividend for the year to 160.0 pence. The
total dividend for 2023 represents 5% growth compared to 2022,
reflecting our confidence in the Group's business model, strategy
and medium to long-term prospects extending our track record of
dividend progress to 56 years.
Market environment
Industrial Production growth
(IP)
|
2023
|
2022
|
|
|
H1
|
H2
|
FY
|
H1
|
H2
|
FY
|
Europe
|
|
-0.1%
|
0.2%
|
0.0%
|
2.2%
|
0.6%
|
1.4%
|
North America
|
|
0.7%
|
0.4%
|
0.5%
|
4.0%
|
2.8%
|
3.4%
|
South America
|
|
-1.1%
|
-1.6%
|
-1.4%
|
1.9%
|
1.3%
|
1.6%
|
Asia ex-China
|
|
-0.6%
|
1.8%
|
0.6%
|
4.0%
|
1.6%
|
2.8%
|
China
|
|
0.8%
|
0.5%
|
0.6%
|
0.5%
|
2.3%
|
1.4%
|
Global
|
|
0.0%
|
0.6%
|
0.3%
|
2.5%
|
1.7%
|
2.1%
|
Source: CHR Economics 26th February 2024
Global industrial production
growth (IP) in 2023 was 0.3% compared to 2.1% in 2022, with lower
growth in all regions. IP was also materially lower than had been
forecast at the beginning of the year (1.4%) with downward
revisions to second half growth particularly marked in North
America and China. China's IP was expected to grow by 2.1% as
it recovered from the weak 1.4% in 2022; instead, it grew by only
0.6% in 2023. Global IP fell sequentially in Q4 by 0.3%
compared to Q3, despite an October 2023 forecast for sequential
growth of 0.7%, evidencing the weakening outlook for industrial
production heading into 2024.
In Biopharm (around 50% of
Watson-Marlow's sales in 2023, down from around 60% in 2022),
customer destocking, which began in the second half of 2022,
continued and the recovery in demand that we had anticipated in the
second half of 2023 did not materialise. During the second half of
2023, our customers began to indicate higher excess inventory
levels than they had originally estimated, with a return to demand
growth not expected until late 2024. Despite the challenges
associated with forecasting short-term demand, the Biopharm
end-markets remain robust and we believe that the underlying growth
in demand has continued at its pre-pandemic rate of over 10% per
annum.
In Semicon (around 11% of ETS
sales in 2023, down from around 18% of proforma 2022 sales), demand
in the first half was lower than we had anticipated and remained
subdued through the second half, with our customers indicating a
return to growth in 2024. Over the medium-term, Semicon remains an
attractive and growing sector. We continue to anticipate strong
demand for our niche solutions for precise thermal controls that
are incorporated by Original Equipment Manufacturers (OEMs) into
Wafer Fabrication Equipment (WFE) utilised in ultra-critical
applications.
Other strategic sectors such as
Food & Beverage, Oil & Gas and Power Generation proved
resilient during 2023, while decarbonisation through
electrification remains a growing strategic imperative for
customers, reflected in the strong demand we have seen for our
products and solutions in Chromalox and Vulcanic.
1 Semicon refers to the
Semiconductor Wafer Fabrication Sector
2 Proforma comparisons
include contributions from Vulcanic and Durex Industries, as if
they had been fully owned by the Group throughout
2022
Strategic progress
Health and Safety#
As a result of our continued focus
on Health and Safety (H&S) improvement, our all-workplace
incident rate (excluding acquisitions) reduced by 11% to 1.55* in
2023.
The Group (excluding acquisitions)
Lost Time Accidents (LTA) rate increased to 0.19* from 0.12* in
2022. The increase is in part attributable to our
strengthened focus on monitoring and reporting. We have also
introduced a category of Serious Lost Time Accidents (SLTA) and,
while this increased from 7 to 8 in 2023, the rate remains low at
0.05%*.
Improving safety standards and
processes in our most recent acquisitions, Vulcanic and Durex
Industries, remains a key priority as we integrate these businesses
into ETS. The all-workplace incident rate, LTA and SLTA rates
of the two businesses in 2023 (7.55*, 1.32* and 0.47* respectively)
reflect the lower priority that was given to measurement and
processes around H&S under previous ownership. Both
Vulcanic and Durex Industries have embraced our strong H&S
focus, allowing us to build an active improvement
programme.
In 2023, we introduced a five-year
Group Safety Excellence Framework across all three Businesses. The
framework aims to establish consistent oversight, align standards
and reduce risk across all our operating companies globally, as
well as evolving our H&S culture. Material areas of
progress in 2023 included completion of an inventory and risk
assessment of all machinery and expanding the compulsory personal
protective equipment protocols. In 2024, we will conduct a global
survey to better understand our H&S culture, complete a
baseline of statutory inspections and introduce training to help
our colleagues complete root cause analysis. In addition, as
part of our commitment to continuous improvement, we have also
commissioned an independent review of our approach to
H&S.
# We recognise the need to
improve safety performance in our recent acquisitions.
Therefore, Group data excludes acquisitions data, which is reported
separately.
* Per 100,000 work
hours.
Expanding our addressable market
All three Group Businesses have
continued to develop new solutions, supporting our direct sales
engineers to drive growth in target sectors.
STS developed a new Customer Value
Proposition to support lithium mining and the related electric
vehicle battery sector, helping to expand our addressable market.
Following commercial launch of the Group's 'TargetZero'
solutions, STS has begun to build a pipeline of long-term
opportunities amongst its extensive global customer base.
Sales in 2023 included the 'ElectroFit' (a retrofit electric
thermal solution to replace gas fired burners in steam generating
boilers) installation at a Diageo site in Turkey (with a second to
follow in 2024); a first fit 'SteamVolt' (electric boiler solution
developed in partnership with our boiler OEM customers)
installation for a global Food & Beverage customer in
Argentina; and several UK installations of the Steam Battery (a
storage solution for steam that can be generated by renewable
energy or when electricity costs are at their
lowest).
In ETS, Chromalox and Vulcanic
have also continued to develop their decarbonisation project
pipelines and drive penetration of Medium Voltage technology.
Watson-Marlow successfully
transformed its operating model in the mining sector in Australia
from a distributor-led approach to direct sales, helping to build
customer proximity and strengthen its competitive advantage.
Watson-Marlow also launched an important
high flowrate range extension for its Qdos pump, targeting the
industrial liquid/solid separation market which is an attractive
new area of growth.
We also continued to make progress
in implementing our digital strategy with an acceleration in the
number of STS operating locations and customers that are digitally
connected through the Cotopaxi platform, to support solution
generation. Watson-Marlow has developed a number of
machine-learning protocols aimed at delivering preventative
maintenance benefits which will shortly be piloted in a number of
sites within the mining sector.
Optimising supply chain effectiveness
Across the Group, we measure
customer service levels using a number of metrics including
on-time-to-request (OTTR). STS notably achieved a material
improvement in its 2023 OTTR performance that had been impacted by
supply chain challenges during 2022.
Watson-Marlow established a
five-step process to drive operational excellence and efficiencies
across its supply sites by delivering ongoing improvements in
safety, productivity and procurement practices.
In October, ETS began construction
of an expansion to Chromalox's manufacturing site in Ogden, Utah
(USA), which will be dedicated to Medium Voltage heating solutions.
The US$58 million project is expected to be completed towards
the end of 2024, with production ramping-up in 2025.
Operating sustainably
The Group (excluding acquisitions)
continued to improve its sustainability footprint. Energy
usage was down by 8% compared to 2022, which supported a reduction
of 6% in our absolute scope 1 and 2 market-based greenhouse gas
emissions compared to 2022. To date we have achieved a 45%
reduction against our 2019 baseline and are on track to achieve our
targeted reduction of 50% by 2025. We now have green energy
contracts in place for over 60% of the Group's electricity usage
and made further progress in implementing Project ClearSky which
will materially decarbonise the STS manufacturing facility in
Cheltenham (UK).
Water consumption has also reduced
across the Group, down by 20% compared to 2022. Building on
the momentum of 78 biodiversity projects completed in 2022, a
further 135 biodiversity projects were completed in 2023. An
area where we recognise the need to make additional progress is
reducing the Group's total waste sent to landfill, which remained
at 10% in 2023, with additional resource added in this area to help
deliver our target of 0% waste to landfill by 2025.
Volunteering and community engagement are key elements of our One
Planet Sustainability Strategy and 3,280 colleagues participated in
volunteering activities (36% of the total number of colleagues),
with the hours contributed rising by 13% compared to
2022.
Our Sustainability Strategy is
being deployed within Vulcanic and Durex Industries.
Acquisitions and Disposals
During the year we continued to
focus on the onboarding of Vulcanic and Durex Industries into ETS
and the wider Group.
Our acquisition strategy is built
around developing our suite of products and solutions with new and
enhanced capabilities together with broadening our global
presence. In July, we completed the acquisition of a 15%
stake in Kyoto Group (Euronext ticker: KYOTO) as part of a
strategic investment agreement alongside Iberdrola (IBE ticker:
Iberdrola S.A.) to accelerate the decarbonisation of industrial
process heat with Kyoto's proprietary 'Heatcube', a molten salt
thermal energy storage solution. Through Vulcanic, we have
been working with Kyoto since 2021 to provide the electric
immersion heater and power control systems of 'Heatcube'. Our
investment and partnership will support the commercial and
technological development of electrical heaters for existing and
future generations of 'Heatcube' and help drive market
adoption.
In August 2023, Gestra (part of
STS) acquired a small distributor in Malaysia, with whom they have
worked closely in the past, to enhance our local presence and
engineering capability to develop tailored solutions for the local
customer base.
Further details of the operational progress made by each
Business are set out in the Operating Review.
Group Executive Committee membership
For the majority of 2023, the
Group Executive Committee (GEC) comprised the Managing Directors of
our three Businesses, as well as key functional leaders across
Finance, HR, Sustainability and Legal. In September 2023, we
expanded GEC with the appointment of Maria Wilson, Group Digital
Director. Phil Scott joined the GEC in January 2024,
following his appointment as Interim Chief Financial Officer
(CFO). In the summer, we will be joined by Louisa Burdett,
who was appointed CFO in December 2023, and Céline Barroche who
takes over as Group General Counsel and Company Secretary,
succeeding Andy Robson who is retiring from the Group later this
year. I'm delighted to have such a strong, capable and
diverse leadership team.
Outlook and 2024 guidance
CHR's forecast for 2024 IP has
reduced materially from the 2.6% expected in October 2023 to 1.7%
currently, with growth weighted towards the second half (H1: 1.2%;
H2: 2.1%). Against a backdrop of geopolitical unrest and
continuing macroeconomic uncertainty, we remain cautious about the
outlook for IP in 2024, particularly the forecast improvement in
the second half.
If exchange rates at the end of
February were to prevail for the remainder of the year, there would
be a headwind impact of approximately 3% to 2023 sales and
approximately 5% to 2023 adjusted operating
profit.
In 2024, we anticipate mid to
high-single-digit organic growth in Group revenues and low
double-digit organic growth in Group adjusted operating
profit, supported by our proven ability to
grow ahead of IP and increased Biopharm and Semicon demand in the
latter part of the year.
After absorbing the exchange rate
headwinds outlined above, we expect modest progress in the Group
adjusted operating profit margin compared to the 20.7% achieved in
2023. Adjusted operating profit in 2024 will be more second
half weighted than usual, reflecting: exchange rate headwinds; the
reversal of cost containment measures in the first half; and strong
demand growth in the second half.
We anticipate adjusted cash
conversion of approximately 75% in 2024 with capital expenditure as
a proportion of sales of approximately 7%.
Medium-long term
Over the last decade we have
evolved to become a highly differentiated specialist engineering
Group of three complementary Businesses with strong capabilities in
high value niche markets. Our products and solutions are
critical to the operating efficiency and safety of our customers'
industrial processes and increasingly, their sustainability
goals. Our business model and strategy have delivered a track
record of growing organically ahead of IP and industry-leading
margins. Leveraging this uniquely differentiated business
model to take advantage of the significant opportunities we have in
long-term growth markets such as thermal efficiency, fluid path
technology and decarbonisation, will enable us to continue
delivering sustainable compounding growth at attractive margins
over the coming years.
FINANCIAL PERFORMANCE
£m
|
FY
2022
|
Exchange
|
Organic
|
Acquisitions & disposals*
|
FY
2023
|
Organic
|
Reported
|
Revenue
|
1,610.6
|
(27.2)
|
(16.0)
|
115.2
|
1,682.6
|
-1%
|
+4%
|
Adjusted operating
profit
|
380.2
|
(7.1)
|
(45.9)
|
21.9
|
349.1
|
-12%
|
-8%
|
Adjusted operating profit
margin
|
23.6%
|
|
|
|
20.7%
|
-270bps
|
-290bps
|
Statutory operating
profit
|
318.8
|
|
|
|
284.4
|
|
-11%
|
Statutory operating profit
margin
|
19.8%
|
|
|
|
16.9%
|
|
-290bps
|
*Results include the impact of the
acquisition of Vulcanic and Durex Industries and the treatment of
our Russian operating companies as disposals from the date at which
the Group suspended all trading with and within Russia.
To aid comparability with the prior year we refer to both
organic and proforma performance measures in the commentary below.
Organic performance measures include the contribution of Vulcanic
and Durex Industries only for the like-for-like periods of
ownership. Proforma comparisons include contribution from Vulcanic
and Durex Industries, as if they had been fully owned by the Group
throughout 2022.
Sales
Group sales grew by 4%, with full
year contributions from Vulcanic and Durex Industries (acquired in
late 2022) partly offset by the disposal of our Russian operations,
which had a small adverse impact. Group sales were 1% lower
organically, compared to 2022, being 2% higher in the first half
and 4% lower in the second half.
Organic sales growth in STS (8%)
was significantly ahead of IP albeit with strong first half growth
of 15% moderating to 2% in the second half. Second half
trading was characterised by weakening macroeconomic conditions,
especially in China and Germany. Large project orders were
higher, compared to 2022, with growth significantly weighted to the
first half of the year, reflecting customers' weakening confidence
in the economic outlook and reduction in capital investment through
the course of the year.
Organic sales growth in ETS (2%)
was supported by demand from industrial process heating customers
in Chromalox. Thermocoax sales were flat, compared to 2022,
due to lower demand from Semicon customers. Chromalox's
manufacturing facility in Ogden, Utah (USA) continued to implement
operational improvements aimed at increasing throughput, but sales
lagged the even stronger growth in demand for bespoke solutions
that deliver decarbonisation benefits. We remain focused on
delivering higher sales from Ogden while also completing the
facility expansion.
On a proforma basis, Vulcanic
sales were higher, also supported by demand from industrial process
heating customers. However, this growth was more than offset
by significantly lower sales in Durex Industries due to lower
demand from Semicon customers (accounting for approximately 55% of
Durex Industries sales in 2022), with combined proforma sales down
by 6%.
Watson-Marlow sales were down by
19% organically, driven by ongoing destocking by Biopharm
customers, which began in the second half of 2022. During
2023, the organic decline in Biopharm sales was greater in the
first half than in the second half as a result of the more
challenging comparator. Biopharm sales remained broadly flat
in the second half compared to the first half. Sales to
Process Industries customers, which are more directly correlated to
IP, were broadly flat in the first half, compared to 2022. In
the second half of 2023, Process Industries demand was impacted by
the weakening macroeconomic outlook, with sales broadly similar to
the first half.
Adjusted operating profit
Group adjusted operating profit
was down 8%, or 12% organically.
Strong organic growth in adjusted operating profit in STS of 15%,
driven by higher sales and cost containment initiatives, was offset
by organic declines in operating profit in ETS (4%) and
Watson-Marlow (43%). Watson-Marlow's adjusted operating
profit includes a one-off charge in respect of excess Biopharm
inventories in the second half.
Corporate expenses, which are
included in adjusted operating profit, grew by 8% to £27.8 million
(2022: £25.8 million). This increase reflects ongoing
investment to support key strategic initiatives, partially offset
by cost containment measures and reduced variable
compensation. We expect corporate expenses in 2024 to
increase at more than twice the rate of Group organic sales growth
due to: increased investment in strategic initiatives; the reversal
of cost containment measures in the first half; and an increase in
variable compensation, subject to performance targets being
achieved.
Adjusted operating profit margin
Group adjusted operating profit
margin of 20.7% was down 270 bps organically, reflecting the impact
of lower sales from our higher margin businesses, partially
mitigated by strong price discipline even as cost inflationary
pressures eased and the benefits of early restructuring and cost
containment actions.
STS adjusted operating profit margin of 24.6% saw strong organic
progression (up 140 bps), reflecting sales growth, cost containment
initiatives and strong pricing discipline. Sequentially, the
second half margin was slightly higher than the first half
margin. However, the second half margin was impacted by
weakening IP in China and Germany as well as a slowdown in large
projects sales, resulting in a smaller organic increase than in the
first half, compared to 2022.
The increase in the STS adjusted
operating profit margin was offset by organic declines in ETS (90
bps) and Watson-Marlow (1,030 bps).
The organic decline in the ETS
adjusted operating profit margin primarily reflects the impact of
lower sales to customers in the higher margin Semicon sector, but
also investments in onboarding costs for Vulcanic and Durex
Industries and ongoing operational improvement initiatives in
Chromalox's Ogden facility. On a proforma basis ETS adjusted
profit margin (15.6%) was 300 bps lower, compared to
2022.
Chromalox and Thermocoax combined
adjusted operating profit margin in the second half of 2023 was
above both the first half of the year and the second half of
2022. Excluding onboarding costs, Vulcanic adjusted operating
profit margin in 2023 was also higher, compared to 2022.
Durex Industries suffered a significant decline in adjusted
operating profit margin as a result of lower Semicon demand despite
cost actions.
Watson-Marlow's adjusted operating
profit margin of 23.8% fell by 1,030 bps organically.
Although sales were broadly similar across the first half and
second half, the second half adjusted operating profit margin
benefited from restructuring actions taken during the first half,
offset by a one-off charge in respect of excess Biopharm
inventories.
Statutory operating profit and margin
Statutory operating profit decreased
by 11% to £284.4 million (2022: £318.8 million) and the statutory
operating profit margin of 16.9% was down 290 bps (2022:
19.8%). Statutory operating profit and statutory operating
profit margin are impacted by the same drivers as explained in the
adjusted operating profit sections above, as well as the
reconciling items detailed below:
●
|
Charges of £5.7 million relating
to the acquisitions of Vulcanic and Gestra Malaysia. Included
within this amount is a charge of £4.9 million which represents the
fair value movement in deferred consideration payable by Vulcanic
in relation to the acquisition of EML Manufacturing LLC in
2021
|
●
|
A charge of £37.2 million (2022:
£23.7 million) for the amortisation of acquisition-related
intangible assets. The year-on-year increase was driven by a
full year of amortisation of the intangible assets relating to
Vulcanic and Durex Industries which were acquired in late
2022
|
●
|
A charge of £1.3 million from the
reversal of fair value adjustments to inventory on the acquisition
of Vulcanic
|
●
|
A profit of £0.4 million on the
disposal of Econotherm (UK) Ltd, an associate investment
|
●
|
A restructuring charge of £7.5
million in Watson-Marlow to appropriately right-size manufacturing
capacity and reduce overhead support costs in order to offset the
adverse impact of lower sales volumes; and a £1.8 million charge in
relation to the impairment of non-current assets in
Watson-Marlow
|
●
|
A credit of £2.3 million relating
to the release of the provision held in Chromalox for the
restructuring of its manufacturing operation in Soissons
(France)
|
●
|
A one-off impairment charge of
£13.9 million relating to a global ERP programme implementation
within STS (further details are set out in the STS operating
review)
|
Net financing expense
Net financing expenses increased
to £39.9 million (2022: £10.7 million) comprising £35.6 million of
net bank interest (2022: £8.4 million), £2.1 million of interest on
pension liabilities (2022: £0.8 million) and £2.2 million of
interest on lease liabilities (2022: £1.5 million). Bank
interest increased due to the full year impact of higher net debt
following the acquisitions of Vulcanic and Durex Industries at the
end of 2022, together with the refinancing of maturing fixed rate
debt at higher interest coupons due to increases in market interest
rates.
Profit before tax
Adjusted profit before tax was
down 17% to £309.2 million (2022: £370.6 million), driven by an 8%
decrease in adjusted operating profit and additional net financing
expense. Statutory profit before tax was down 21% to £244.5
million (2022: £308.1 million). The reconciling items between
adjusted profit before tax and statutory profit before tax are
shown above and in the Appendix to the Financial
Statements.
Taxation
The Group tax rate reflects the
blended average of rates in tax jurisdictions around the world in
which the Group operates. As expected, the Group adjusted
effective tax rate increased by 50 bps to 25.5% (2022: 25.0%) and
on a statutory basis the Group effective tax rate was 24.7% (2022:
27.0%). The increase in the Group adjusted effective tax rate
was driven by changes in the Group's profit mix by tax
jurisdiction, including the impact of a full year of ownership of
Vulcanic and Durex Industries, together with the impact of
increased withholding tax on intra-Group dividend payments when
combined with lower adjusted profit.
The Group is subject to a local tax
adjustment in Argentina that seeks to offset the impact of
inflation on taxable profits. Given the current level of
inflation in Argentina, this has a meaningful impact on the
effective tax rate. While we include the expected impact of
this adjustment in our guidance for the effective tax rate, this is
difficult to accurately forecast given the current volatility of
Argentinian inflation.
The Group monitors income tax
developments in the countries in which it operates, including the
OECD Base Erosion and Profit Shifting (BEPS) initiative to set a
minimum global tax rate of 15% (Pillar Two). The main
jurisdiction where this initiative may impact the Group is in
Argentina as the impact of the inflation adjustment may result in a
local tax rate that falls below 15%. As noted above, given
the volatility of Argentinian inflation it is difficult to
accurately forecast its impact on the Group's tax charge. The
Group is continuing to monitor the impact of the Pillar Two income
taxes legislation on its future financial performance.
On 8th June 2022, the European Union
(EU) General Court published its decision on the appeals for
annulment made against the European Commission's (EC) 2019 decision
that certain aspects of the UK's Controlled Foreign Company regime
constituted State Aid, finding in favour of the EC. The UK
Government has appealed the decision of the EU General Court.
Whilst the EU General Court ruling was in favour of the EC,
our assessment is that there are grounds for successful appeal.
As a result, we have continued to recognise a receivable of
£4.9 million in the Consolidated Statement of Financial Position.
This relates to the full amount paid to HM Revenue & Customs
for Charging Notices received in 2021. We have not recognised
a receivable for any repayment interest on the £4.9 million.
The Group has not received a Charging Notice for either the
benefit received prior to 2017, which is estimated to be £2.9
million, or the benefit received during 2019 of £1.1 million.
No provisions have currently been recognised relating to
these amounts and therefore they remain a contingent liability at
31st December 2023.
For 2024, we currently anticipate
that the Group adjusted effective tax rate will increase by up to
100 bps, compared to 2023, to approximately 26.5% based on a
forecast mix of profits and level of inflation in
Argentina.
Earnings per share
Adjusted basic earnings per share
decreased by 17% to 312.4 pence (2022: 377.2 pence), consistent
with the decrease in adjusted operating profit and increased net
financing costs. Statutory basic earnings per share were 249.5
pence (2022: 305.1 pence). The statutory fully diluted
earnings per share were not materially different to the statutory
basic earnings per share in either year.
Dividends
The Group has a progressive
dividend policy, the aim of which is to provide sustainable,
affordable dividend growth. The Group has a 55-year track
record of dividend progress with a compound annual increase of 11%
over that period.
The Board is proposing a final
dividend of 114.0 pence per share for 2023 (2022: 109.5 pence)
payable on 24th May 2024 to shareholders on the register at 26th
April 2024. Together with the interim dividend of 46.0 pence
per share (2022: 42.5 pence), the total dividend for the year is
160.0 pence per share, an increase of 5% on the total dividend of
152.0 pence per share in 2022. Dividend cover in 2023 will
reduce to 2.0x, the lower end of the Group's target range of 2.0x
to 2.5x, improving over the medium-term as a recovery in demand
drives earnings growth.
The total amount paid in dividends
during the year was £114.9 million, 11% above the £103.6 million
paid in 2022.
Currency movements
The Group's Income Statement and
Statement of Financial Position are exposed to movements in a wide
range of different currencies. This stems from our direct sales
business model, with a large number of local operating companies.
These currency exposures and risks are managed through a rigorously
applied Treasury Policy, typically using centrally managed and
approved simple forward contracts to mitigate exposures to forecast
future cash flows and avoiding the use of complex derivative
transactions. The largest individual currency exposures are to the
euro, US dollar, Chinese renminbi and Korean won. Whilst the size
of the Group's businesses in Argentina is immaterial to the
consolidated financial results, the level of volatility in the
Argentinian peso has had a negative translational impact on Group
reported financial performance. While currency effects can be
significant, the structure of the Group provides some mitigation
through our regional manufacturing presence, diverse spread of
geographic locations and through the natural hedge of having a high
proportion of our overhead costs in the local currencies of our
operating companies.
Currency movements negatively
impacted adjusted operating profit by 2% with a transactional
benefit of £5.9 million being offset by a translational downside of
£13.0 million. The translation downside reflects the impact
of the strengthening of sterling in 2023 against the currencies in
which the Group generated its adjusted operating profit. The
main transactional exposure flow affecting the Group is the export
of products from our factories in the UK, invoiced in sterling,
less the import of goods from overseas Group factories and third
parties priced predominately in euros and US dollars. The net
exposure to transactional currency movements is approximately £120
million.
If exchange rates at the end of
February were to prevail for the remainder of 2024, there would be
a headwind impact of approximately 3% on 2023 sales, or
approximately 2% excluding the significant devaluation of the
Argentine peso in December 2023. On the same basis, the headwind
impact on 2023 adjusted operating profit would be approximately 5%,
or approximately 2% excluding the Argentine peso
devaluation.
Financial Position and Cash Flow
Capital employed
|
2023
£m
|
2022
£m
|
Property, plant and
equipment
|
415.1
|
384.5
|
Right-of-use assets
|
98.4
|
67.2
|
Software & development
costs
|
42.3
|
44.5
|
Non-current prepayments
|
1.9
|
2.0
|
Inventories
|
285.2
|
290.0
|
Trade receivables
|
299.8
|
341.1
|
Other current assets
|
71.4
|
79.6
|
Tax recoverable
|
13.6
|
19.0
|
Trade, other payables and current
provisions
|
(260.7)
|
(295.0)
|
Current tax payable
|
(28.3)
|
(40.4)
|
Capital employed
|
938.7
|
892.5
|
Acquired intangibles including
goodwill
|
1,087.0
|
1,159.1
|
Investment in Associate
|
3.0
|
-
|
Post-retirement
benefits
|
(51.4)
|
(52.1)
|
Net deferred tax
|
(37.2)
|
(59.1)
|
Non-current provisions and
long-term payables
|
(19.0)
|
(15.0)
|
Lease liabilities
|
(96.7)
|
(65.2)
|
Net debt
|
(666.7)
|
(690.4)
|
Net assets
|
1,157.7
|
1,169.8
|
Adjusted operating
profit
|
349.1
|
380.2
|
Adjusted operating profit
(excluding acquisitions, disposals and leases)
|
317.7
|
369.9
|
Average capital
employed
|
915.6
|
775.9
|
Average capital employed
(excluding acquisitions, disposals and leases)
|
772.4
|
677.5
|
Return on capital employed
|
38.1%
|
49.0%
|
Return on capital employed (excluding acquisitions, disposals
and leases)
|
41.1%
|
54.6%
|
Capital employed increased by
£46.2 million to £938.7 million at 31st December 2023.
Tangible fixed assets (property, plant & equipment and
right-of-use-assets) increased by £61.8 million to £513.5 million,
principally as a result of the completion of the new manufacturing
facility for Watson-Marlow in Devens, Massachusetts (USA) together
with the commencement of the construction project to expand the
Chromalox facility in Ogden, Utah (USA) in order to meet customer
demand for Medium Voltage decarbonisation solutions.
Net capital expenditure in the
period was £102.8 million. This was lower than anticipated as a
result of changes in the phasing of payments on a number of large
capital projects. In 2024, we expect the ratio of capital
expenditure to sales to increase to 7% reflecting the impact of
phasing delays from 2023 together with the ongoing expansion of the
Ogden facility.
The capital intensity of our
business is low with historic capital expenditure typically
amounting to between 4% and 6% of sales. Excluding our
investment in new construction projects, capital expenditure, as a
percentage of sales, would be at the low end of our typical
range.
Total working capital increased by
£9.3 million and the ratio of working capital to sales was, as
expected, 22.8% (2022: 22.8% on a proforma basis). It is
expected that the working capital to sales ratio will remain at a
consistent level in 2024.
Return on capital employed (ROCE)
ROCE reduced by 1,090 bps to 38.1%
(2022: 49.0%). Excluding the impacts of acquisitions, disposals and
leases, ROCE decreased by 1,350 bps to 41.1% (2022: 54.6%), driven
by capital investments as well as the impact of the challenging
trading environment on adjusted operating profit. ROCE is
defined in the Appendix to the Financial Statements.
Return on invested capital (ROIC)
ROIC decreased by 480 bps to 13.5%
(2022: 18.3%). Excluding the impacts of acquisitions,
disposals and leases, ROIC decreased by 430 bps to 17.7% (2022:
22.0%), driven by a decrease in adjusted operating profit after
tax. ROIC is defined in the Appendix to the Financial
Statements.
Adjusted cash flow
Adjusted Cash flow
|
2023
£m
|
2022
£m
|
Adjusted operating
profit
|
349.1
|
380.2
|
Depreciation and amortisation
(excl. leased assets)
|
44.2
|
36.0
|
Depreciation of leased
assets
|
16.2
|
13.4
|
Cash payments to pension schemes
more than the charge to adjusted operating profit
|
(5.7)
|
(5.3)
|
Equity settled share
plans
|
6.1
|
8.9
|
Working capital changes
|
(9.3)
|
(91.9)
|
Repayments of principal under
lease liabilities
|
(16.1)
|
(12.9)
|
Capital expenditure (including
software and development)
|
(102.8)
|
(117.5)
|
Capital disposals
|
-
|
4.0
|
Adjusted cash from operations
|
281.7
|
214.9
|
Net interest
|
(37.7)
|
(8.8)
|
Income taxes paid
|
(90.7)
|
(90.0)
|
Adjusted Free cash flow
|
153.3
|
116.1
|
Net dividends paid
|
(114.9)
|
(103.6)
|
Purchase of employee benefit trust
shares/Proceeds from issue of shares
|
(10.8)
|
(19.0)
|
(Acquisitions)/Disposals of
subsidiaries
|
(7.7)
|
(538.3)
|
Restructuring costs
|
(8.1)
|
(3.2)
|
Cash flow for the year
|
11.8
|
(548.0)
|
Exchange movements
|
11.9
|
(11.9)
|
Opening net debt
|
(690.4)
|
(130.5)
|
Net debt at 31 December
|
(666.7)
|
(690.4)
|
Lease liability
|
(96.7)
|
(65.2)
|
Net debt and lease liability at 31 December
|
(763.4)
|
(755.6)
|
Adjusted cash from operations is a
measure of the cash flow generated from our operating companies.
A reconciliation with statutory operating cash flow can be
found in the Appendix to the Financial Statements.
Adjusted cash from operations of
£281.7 million (2022: £214.9 million) was up £66.8 million,
resulting in an improved adjusted cash conversion of 81% (2022:
57%). The improvement in cash conversion was driven by lower
than anticipated capital expenditure (as outlined above) together
with a lower working capital outflow which offset the fall in
adjusted operating profit.
Tax paid in the period of £90.7
million (2022: £90.0 million) has remained relatively consistent
year-on-year. Adjusted free cash flow of £153.3 million
(2022: £116.1 million) has increased by 32% driven by improved
adjusted cash from operations but negatively impacted by increased
net interest payments in the period.
Dividend payments were £114.9
million (2022: £103.6 million) including payments to minority
shareholders, and reflect the final dividend for 2022, as well as
the interim dividend for 2023.
Share purchases, net of new shares
issued for the Group's various employee share schemes, resulted in
a cash outflow of £10.8 million (2022: £19.0 million) reflecting a
lower vesting of the Group's Performance Share Plan.
Acquisitions (net of disposals)
during the year amounted to £7.7 million (2022: £538.3 million),
primarily reflecting the purchase by Gestra of a local Malaysian
distributor and the acquisition of a 15% stake in Kyoto
Group.
Restructuring spend of £8.1
million relates primarily to the right-sizing of capacity and
overhead support costs undertaken in Watson-Marlow.
The £31.5 million increase in
lease liabilities was largely driven by the lease commitment for
the Watson-Marlow manufacturing facility in Devens, Massachusetts
(USA).
Financing and Liquidity
Net debt (excluding leases) at the
31st December 2023 was £666.7 million (FY 2022: £690.4 million),
with a net debt to EBITDA ratio of 1.7x (2022: 1.7x on a reported
basis and 1.5x on a proforma basis).
As at the 31st December 2023,
total committed and undrawn debt facilities amounted to £294.5
million alongside a net cash balance of £212.8 million. In the
year, the Group issued €110m of new US Private Placement notes at a
fixed coupon of 4.38% and entered into a Bank Term Loan of €90m in
order to refinance the €225m of 1.05% fixed coupon notes that
matured in September 2023. The average tenor of our debt is over
four years with the next contractual repayment maturity in October
2025. In February 2024, the Group successfully exercised an option
to extend the maturity of our £400 million committed, revolving
credit facility by an additional year to April 2029.
OPERATING
REVIEW
Steam Thermal Solutions
£m
|
FY
2022
|
Exchange
|
Organic
|
Acquisitions & disposals*
|
FY 2023
|
Organic
|
Reported
|
Revenue
|
866.0
|
(25.1)
|
70.5
|
(1.3)
|
910.1
|
+8%
|
+5%
|
Adjusted operating
profit
|
206.1
|
(11.3)
|
29.3
|
(0.1)
|
224.0
|
+15%
|
+9%
|
Adjusted operating profit
margin
|
23.8%
|
|
|
|
24.6%
|
+140bps
|
+80bps
|
Statutory operating
profit
|
196.2
|
|
|
|
205.2
|
|
+5%
|
Statutory operating profit
margin
|
22.7%
|
|
|
|
22.5%
|
|
-20bps
|
*Results include the impact of the
treatment of our Russian operating companies as disposals from the
date at which the Group suspended all trading with and within
Russia.
STS delivered organic sales growth
of 8%, which was significantly ahead of IP across all regions,
despite a challenging macroeconomic outlook that weakened
progressively through the year and particularly during the second
half. Strong first half growth of 15% moderated to 2% in the
second half driven by weaker IP in China and Germany, together with
a slowdown in large orders compared to the first
half.
Against this backdrop we
implemented temporary cost containment measures while preserving
investment and momentum in key growth
initiatives (direct sales effectiveness,
digital connected products and services, and decarbonisation
solutions). As a result, full year adjusted operating profit
of £224 million grew by 15% organically, with adjusted operating
profit margin up 140 bps organically, reflecting price and cost
discipline. Second half adjusted operating profit margin was
slightly higher than in the first half of 2023 and the second half
of 2022.
STS has both sales and
manufacturing operations in Argentina, representing less than 1.5%
of Group sales in 2023. Current levels of inflation and the
extreme volatility in the Argentine peso exchange rate, as
demonstrated by the large devaluation in December 2023, have
created challenging operating conditions. While our local
operating company prices with reference to the US dollar to protect
against operating profit margin erosion, the Group's ability to
repatriate cash generated in Argentina is currently limited.
As a result, we are limiting inward investment into our Argentinian
operations.
Statutory operating profit of
£205.2 million was up 5% from £196.2 million in 2022 and the
statutory operating profit margin of 22.5% decreased by 20 bps.
Since 2018, STS has been engaged
in a project to upgrade its ERP systems, known as Project OPAL.
Over time, the scope of the project has expanded substantially to
include a wider range of business applications. In parallel, the
external technology market has continued to evolve and the Group
has also taken the decision to implement consistent ERP solutions
across all three Businesses. Within STS, this will enhance future
capability, in addition to leveraging the scale of the broader
Group. This has resulted in an impairment charge to statutory
operating profit of £13.9 million in relation to existing assets
which will no longer provide future economic benefit.
Operating highlights
We launched our
'TargetZero' solutions in November 2022, to
support the decarbonisation of industrial steam generation, and the
first installation of 'ElectroFit' was completed during 2023 for
Diageo in Turkey. Interest in these solutions continues to
strengthen and decarbonisation remains a key long-term growth
opportunity for STS, working in collaboration with ETS.
However, the rate of adoption will depend on several factors
including: the development of local infrastructure for the
generation and transmission of electricity; the comparative cost of
natural gas and electricity impacting operating costs as a result
of decarbonisation; and customer ambition in achieving net zero
greenhouse gas emissions, as well as their willingness to invest
behind delivery of their targets.
As an industry leader, STS
organised and chaired the first 'Sustainable Steam Symposium' in
2023 at Brunel University. This Symposium was centred around
the latest developments in research, technology trials and pilot
projects within the steam and thermal solutions industry, with a
focus on the decarbonisation of steam generation and energy-saving
innovations.
Throughout the year we have
continued to develop new digitally enhanced customer solutions that
extend our expertise beyond the onsite services provided by our
field engineers. We saw a doubling in the number of connected
customer sites, an increase in the number of reports generated for
customers and strong sales of incremental products and services
attributed directly to digital connections. By driving
adoption of digital connections and developing our direct sales
capability to deliver solutions based on richer data and additional
insights, we believe we are laying strong foundations for further
digitally enabled growth in STS.
STS has continued to expand its
addressable market through the development of new solutions,
targeting high growth sectors. For example, STS delivered
exceptional growth in the lithium-ion
battery sector in 2023, particularly in Asia Pacific, where we now
have over 100 customers.
In line with our strategy of
continuing to develop our local presence, in August 2023
Gestra acquired a distributor in Kuala Lumpur,
Malaysia. This acquisition has expanded our local direct
sales team as well as our customer base allowing us to further
implement our business model focused on solution-selling and
self-generated sales.
2024 outlook
We anticipate mid-single-digit
organic sales growth in STS. Adjusted operating profit margin
is expected to be lower than in 2023, reflecting exchange rate
headwinds, the reversal of 2023 cost containment measures and
increased revenue investments to support future growth.
Electric Thermal Solutions
£m
|
FY
2022
|
Exchange
|
Organic
|
Acquisitions & disposals*
|
FY 2023
|
Organic
|
Reported
|
Revenue
|
256.1
|
0.3
|
4.1
|
118.0
|
378.5
|
+2%
|
+48%
|
Adjusted operating
profit
|
39.9
|
(1.0)
|
(1.7)
|
22.0
|
59.2
|
-4%
|
+48%
|
Adjusted operating profit
margin
|
15.6%
|
|
|
|
15.6%
|
-90bps
|
+0bps
|
Statutory operating
profit
|
7.3
|
|
|
|
25.8
|
|
+253%
|
Statutory operating profit
margin
|
2.9%
|
|
|
|
6.8%
|
|
+390bps
|
*Results include the impact of the
acquisitions of Vulcanic and Durex Industries.
While IP remains a key underlying
driver of growth in ETS, secular trends in the decarbonisation and
Semicon markets are important additional drivers. As
expected, Semicon (18% of ETS proforma sales in 2022) sector demand
remained weak through 2023, driven by customer destocking.
Both Durex Industries and to a lesser extent Thermocoax (that focus
on industrial equipment heating solutions) were impacted by slowing
Semicon demand.
Demand growth in Chromalox and
Vulcanic (that focus on industrial process heating solutions) was
significantly ahead of IP. Growth was strongest in
strategically important sectors such as Energy Transition, which
includes decarbonisation solutions, leading to a significantly
enhanced order book.
ETS sales were up 48% reflecting
the contribution from the acquisitions of Vulcanic and Durex
Industries. Excluding this contribution, sales were up 2%
organically (H1: up 7%; H2: down 2%), reflecting growth in
Chromalox but lower Semicon demand impacting Thermocoax sales,
particularly in the second half.
Chromalox's manufacturing facility
in Ogden, Utah (USA) continued to implement operational
improvements aimed at increasing throughput but sales lagged the
even stronger growth in demand for bespoke solutions that deliver
decarbonisation benefits. We remain focused on delivering
higher sales from Ogden while also completing the facility
expansion. On a proforma basis, the combined sales of
Vulcanic and Durex Industries were down 6%, compared to 2022, with
strong growth at Vulcanic offset by lower sales at Durex
Industries, which was impacted by lower Semicon demand.
ETS adjusted operating profit was
up 48% due to the contribution from the acquisitions of Vulcanic
and Durex Industries. Excluding the acquisitions, adjusted
operating profit was broadly flat, compared to 2022, with adjusted
operating profit margin impacted by continued investments in
operational improvements in Chromalox and weaker growth in higher
margin Thermocoax. Chromalox and Thermocoax combined adjusted
operating profit margin in the second half of 2023 was above both
the first half of the year and the second half of
2022.
On a proforma basis, the combined
adjusted operating profit margin of the acquisitions was down
year-on-year, driven by the impact of lower Semicon demand on Durex
Industries, as well as investments in safety, systems and processes
to more closely align the acquisitions with the Group's operating
standards. The benefit of early cost actions taken at Durex
Industries helped to mitigate the margin decline. Excluding
onboarding costs, Vulcanic adjusted operating profit margin in 2023
was higher, compared to 2022.
ETS statutory operating profit was
up 253% compared to 2022, reflecting restructuring charges relating
to Chromalox EMEA that impacted the 2022 result, with the statutory
operating profit margin of 6.8% up 390 bps.
Operating highlights
The integration of Vulcanic and
Durex Industries, one of ETS's key priorities in 2023, continued to
progress well with high levels of collaboration between the Chromalox and Vulcanic teams in
areas such as sales training, deployment of pricing tools and new
product development. Our dual brand strategy is being
implemented in Vulcanic and Chromalox with particular benefits seen
for customers in EMEA, as we migrated manufacturing of Chromalox
products to Vulcanic sites in France and Spain following the
closure of Chromalox's Soissons (France) site in 2022. ETS
also completed a site rationalisation
between Thermocoax and Durex Industries with the transfer of
production from our Alpharetta, Georgia (USA) facility to Carey,
Illinois (USA). Good progress continues to be made on
improving safety and sustainability in line with Group operating
standards.
Chromalox and Vulcanic have
continued to drive growth in their target sectors, particularly
focused on the industrial electrification opportunity, which has
resulted in a significant increase in the ETS order book.
During 2023, Chromalox supported Tesla
with the development of its Cyber Truck manufacturing facility in
San Antonio, Texas (USA).
In October, ETS began construction
of an expansion to Chromalox's manufacturing site in Ogden, Utah
(USA), which will be dedicated to Medium Voltage heating solutions.
The US$58 million expansion is expected to be completed
towards the end of 2024, with production ramping-up in 2025.
In support of our commitment to sustainability, the facility will
install ground source heat pump systems to efficiently heat and
cool the facility with renewable energy. In addition,
Chromalox's manufacturing facility in Nuevo Laredo (Mexico)
completed a second solar panel system installation, which will lead
to significant energy savings and emissions reductions.
2024 outlook
We anticipate high-single-digit
organic sales growth in ETS supported by a return to demand growth
in Semicon. Adjusted operating profit margin progress will be
supported by improved operational performance and higher Semicon
revenues, partly offset by onboarding costs in Vulcanic and Durex
Industries, as well as pre-production costs for the expanded Ogden
facility.
Watson-Marlow
£m
|
FY
2022
|
Exchange
|
Organic
|
Acquisitions & disposals*
|
FY 2023
|
Organic
|
Reported
|
Revenue
|
488.5
|
(2.4)
|
(90.6)
|
(1.5)
|
394.0
|
-19%
|
-19%
|
Adjusted operating
profit
|
160.0
|
5.2
|
(71.5)
|
-
|
93.7
|
-43%
|
-41%
|
Adjusted operating profit
margin
|
32.8%
|
|
|
|
23.8%
|
-1,030bps
|
-900bps
|
Statutory operating
profit
|
154.4
|
|
|
|
81.2
|
|
-47%
|
Statutory operating profit
margin
|
31.6%
|
|
|
|
20.6%
|
|
-1,100bps
|
*Results include the impact of the
treatment of our Russian operating companies as disposals from the
date at which the Group suspended all trading with and within
Russia.
Watson-Marlow's trading continued
to be impacted by customer destocking activity in the Biopharm
sector throughout the year. Underlying demand remains strong, with
Biopharm end-markets continuing to grow at the pre-pandemic rate of
over 10% per annum. However, it became clear through 2023
that this demand would continue to be satisfied by excess inventory
built up during the peak of the COVID pandemic. In
Watson-Marlow this has resulted in Biopharm monthly sales remaining
broadly flat throughout 2023.
Watson-Marlow sales declined by
19% organically, compared to 2022. Biopharm sales (which
accounted for approximately 60% of Watson-Marlow sales in 2022)
declined by close to 30% organically. The organic decline in
Biopharm sales was larger in the first half than in the second half
due to a more challenging comparator, with customer destocking
having materially started in the second half of 2022.
Supported by the continued strong
growth in Biopharm end-markets, we anticipate a return to sales
growth during 2024. As evidenced by market commentary from a
number of larger Biopharm OEMs, which are our customers, the
precise timing and scale of the recovery remains challenging to
predict with a wide range of views spanning from a recovery in the
second half of 2024, through to recovery being delayed into
2025.
Sales to Process Industries
customers, which are more directly correlated to IP, were broadly
flat in the first half, compared to 2022. In the second half
of 2023, Process Industries demand growth was impacted by the
weakening macroeconomic outlook, with sales broadly similar to the
first half. Process Industries sales also remained
significantly ahead of pre-pandemic levels.
The benefits of early actions to
address the weaker trading environment were realised in the second
half of the year, mitigating the impact of lower sales on adjusted
operating profit. While the adjusted operating profit margin
declined by 1,030 bps organically, to 23.8%, the second half margin
was impacted by a one-off charge in respect of excess Biopharm
inventory.
Statutory operating profit was
down 47% compared to 2022, while statutory operating profit margin
was down 1,100 bps, reflecting costs of
£9.3 million to appropriately right-size manufacturing capacity and
reduce overhead support costs.
Operating highlights
Against a backdrop of challenging
trading conditions, we took steps to
offset the adverse impact of lower sales volumes on profitability.
While most of the right-sizing was focused on UK and EMEA
manufacturing operations, Watson-Marlow also closed its Flowsmart
site in Delaware (USA) and transferred manufacturing to its newly
built facility in Devens, Massachusetts (USA).
Restructuring and cost actions
continued to be implemented during the second half, balancing the
need to protect margins with maintaining business-readiness for an
anticipated return to volume growth in 2024.
In this context, we also continued to
invest in developing new products and services.
Watson-Marlow began
incorporating ISO 13485, a quality
management system covering the design and manufacture of medical
devices, into its product development process from October 2023.
This is expected to become a requirement for products sold
into cell and gene therapy markets.
Also in Biopharm, Watson-Marlow
developed 'DriveSure' - a digitally enabled, pre-configurable pump
and drive unit that can be customised for small spaces; and further
developed its unique 'PureSU' (Pure Single-Use) assembly offering,
which represents a powerful example of tailored customer solutions
by providing customised connectivity for the fluid path between
disparate pieces of end-user equipment.
Watson-Marlow continued to expand
its addressable market in Process Industries by developing
solutions for new and emerging sectors. Cell-based meat has
been identified as a high potential area of future growth and
Watson Marlow Germany is working with
'Cultivated B', the first company in the
EU to apply for certification for its product. This
initiative ties into Watson-Marlow's existing Future Foods focus
where sales into precision fermented food manufacturers have more
than doubled since 2021.
The Electric Vehicle (EV) battery
market is another focus sector, especially for Watson-Marlow's
Bredel product range. A key process step in EV battery
manufacture is the production of the Nickel, Cobalt, Manganese
(NCM) Ternary Precursors used in EV battery cathodes.
Peristaltic hose pumps are the ideal technology for mixing
and transferring these chemical slurries, which are vital to scale
up EV battery production to meet global demand. The C42
Bredel pump has been developed to meet the specific technological
needs of this sector.
2024 outlook
We anticipate high-single-digit
organic sales growth supported by a return to growth in Biopharm
demand in the latter part of the year, albeit there are a variety
of views within the industry on the timing and scale of this
recovery. This sales growth is expected to deliver a strong
improvement in adjusted operating profit margin after absorbing the
reversal of 2023 cost containment measures and an increase in
variable compensation.
PRINCIPAL RISKS AND UNCERTAINTIES
The Group has processes in place
to identify, evaluate and mitigate the Principal Risks that could
have an impact on our performance. Following the annual
review of the Risk Register, Principal Risks and the responses from
the bottom-up risk review, as compared to 2022, the following
changes were made:
Increased risks
1. Significant
exchange rate movement - to reflect the increasing volatility
of exchange rates across both developed and developing economies
that we have witnessed in 2023. Mitigations against this risk
include: maintaining a geographic spread of manufacturing;
consideration of exchange rate exposures in the Group's
manufacturing strategy; and entering into hedging arrangements
where appropriate and in line with the Group Treasury Policy on
hedging currency exchange movements.
2. Failure to
realise acquisition objectives - the acquisitions of Vulcanic and
Durex Industries in late 2022 require integration into the Group in
order to align operating standards and deliver our acquisition
objectives. The combined size of these two acquisitions
result in an increased risk should the Group fail to realise its
objectives. The key mitigation against this risk is
regular monitoring of performance against the investment
case.
Decreased risks
1. Loss of
manufacturing output at any Group factory - to reflect lower risk
of disruption than during the COVID pandemic as well as lower risk
of labour and materials shortages than in the previous
year.
2. Loss of a
critical supplier - to reflect lower volatility in our upstream
supply chain as markets have stabilised post the COVID pandemic and
become more resilient in response to continuing geopolitical
uncertainty. The Group has also diversified its supply chain
by selectively expanding its supplier base in order to manage areas
of concentration risk. Inflation in commodities has also
eased.
We remain focused on climate
change as an emerging risk given the increasing likelihood of
climate-related hazards impacting the Group. We worked with a
specialist third-party advisor to assess the likely impact of
extreme weather events on our operating companies and asset
base. The results of the assessment validated that, under
current conditions, the residual impact of climate related risks in
this context is not expected to be significant.
Our Risk Management report and the
full list of Principal Risks, including how they have changed
year-on-year, will be published in our 2023 Annual Report on 28th
March 2024.
Spirax-Sarco Engineering
plc
CONSOLIDATED
STATEMENT OF FINANCIAL POSITION AT 31ST DECEMBER 2023
|
Notes
|
2023
£m
|
2022
£m
|
ASSETS
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and
equipment
|
|
415.1
|
384.5
|
Right-of-use assets
|
|
98.4
|
67.2
|
Goodwill
|
|
680.5
|
703.3
|
Other intangible assets
|
|
448.8
|
500.3
|
Prepayments
|
|
1.9
|
2.0
|
Investment in Associate
|
|
3.0
|
-
|
Taxation recoverable
|
|
4.9
|
5.1
|
Deferred tax assets
|
|
31.0
|
69.0
|
|
|
1,683.6
|
1,731.4
|
Current assets
|
|
|
|
Inventories
|
|
285.2
|
290.0
|
Trade receivables
|
|
299.8
|
341.1
|
Other current assets
|
|
71.4
|
79.6
|
Taxation recoverable
|
|
8.7
|
13.9
|
Cash and cash
equivalents
|
7
|
359.7
|
328.9
|
|
|
1,024.8
|
1,053.5
|
Total assets
|
|
2,708.4
|
2,784.9
|
EQUITY AND LIABILITIES
|
|
|
|
Current liabilities
|
|
|
|
Trade and other
payables
|
|
251.2
|
283.0
|
Provisions
|
|
9.5
|
12.0
|
Bank overdrafts
|
7
|
146.9
|
85.1
|
Current portion of long-term
borrowings
|
7
|
3.6
|
202.9
|
Short-term lease
liabilities
|
7
|
14.5
|
14.1
|
Current tax payable
|
|
28.3
|
40.4
|
|
|
454.0
|
637.5
|
Net current assets
|
|
570.8
|
416.0
|
Non-current liabilities
|
|
|
|
Long-term borrowings
|
7
|
875.9
|
731.3
|
Long-term lease
liabilities
|
7
|
82.2
|
51.1
|
Deferred tax
liabilities
|
|
68.2
|
128.1
|
Post-retirement
benefits
|
|
51.4
|
52.1
|
Provisions
|
|
7.6
|
6.2
|
Long-term payables
|
|
11.4
|
8.8
|
|
|
1,096.7
|
977.6
|
Total liabilities
|
|
1,550.7
|
1,615.1
|
Net assets
|
2
|
1,157.7
|
1,169.8
|
Equity
|
|
|
|
Share capital
|
|
19.8
|
19.8
|
Share premium account
|
|
90.1
|
88.1
|
Translation reserve
|
|
(60.4)
|
17.5
|
Other reserves
|
|
(12.9)
|
(23.4)
|
Retained earnings
|
|
1,120.3
|
1,067.0
|
Equity shareholders'
funds
|
|
1,156.9
|
1,169.0
|
Non-controlling
interest
|
|
0.8
|
0.8
|
Total equity
|
|
1,157.7
|
1,169.8
|
Total equity and liabilities
|
|
2,708.4
|
2,784.9
|
Spirax-Sarco Engineering
plc
CONSOLIDATED INCOME
STATEMENT FOR THE YEAR ENDED 31ST DECEMBER 2023
|
Notes
|
2023
£m
|
2022
£m
|
Revenue
|
2
|
1,682.6
|
1,610.6
|
Operating costs
|
|
(1,398.2)
|
(1,291.8)
|
Operating profit
|
2
|
284.4
|
318.8
|
Financial expenses
|
|
(51.2)
|
(16.3)
|
Financial income
|
|
11.3
|
5.6
|
Net financing expense
|
2,
3
|
(39.9)
|
(10.7)
|
Share of profit/(loss) of
Associate
|
|
-
|
-
|
Profit before taxation
|
|
244.5
|
308.1
|
Taxation
|
4
|
(60.5)
|
(83.1)
|
Profit for the year
|
|
184.0
|
225.0
|
Attributable to:
|
|
|
|
Equity shareholders
|
|
183.6
|
224.7
|
Non-controlling
interest
|
|
0.4
|
0.3
|
Profit for the year
|
|
184.0
|
225.0
|
Earnings per share
|
5
|
|
|
Basic earnings per
share
|
|
249.5p
|
305.1p
|
Diluted earnings per
share
|
|
248.9p
|
304.4p
|
Dividends
|
6
|
|
|
Dividends per share
|
|
160.0p
|
152.0p
|
Dividends paid during the year
(per share)
|
|
155.5p
|
140.0p
|
|
|
|
| |
Spirax-Sarco Engineering
plc
CONSOLIDATED
STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR
ENDED 31ST DECEMBER
2023
|
Notes
|
2023
£m
|
2022
£m
|
Profit for the year
|
|
184.0
|
225.0
|
Items that will not be
reclassified to profit or loss:
|
|
|
|
Remeasurement loss on
post-retirement benefits
|
|
(3.8)
|
(8.3)
|
Deferred tax on remeasurement loss
on post-retirement benefits
|
|
1.1
|
1.8
|
|
|
(2.7)
|
(6.5)
|
Items that may be reclassified
subsequently to profit or loss:
|
|
|
|
Foreign exchange translation and
net investment hedges (loss)/gain
|
|
(77.9)
|
54.8
|
Transfer to Consolidated Income
Statement of cumulative translation differences on disposal of
subsidiaries
|
|
-
|
3.2
|
Gain/(loss) on cash flow hedges
net of tax
|
|
5.0
|
(3.5)
|
|
|
(72.9)
|
54.5
|
Total comprehensive income for the year
|
|
108.4
|
273.0
|
Attributable to:
|
|
|
|
Equity
shareholders
|
|
108.0
|
272.7
|
Non-controlling
interest
|
|
0.4
|
0.3
|
Total comprehensive income for the year
|
|
108.4
|
273.0
|
Spirax-Sarco Engineering
plc
CONSOLIDATED
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31ST DECEMBER
2023
|
Share
Capital
£m
|
Share
Premium
Account
£m
|
Translation
reserve
£m
|
Other
reserves
£m
|
Retained
Earnings
£m
|
Equity shareholders'
funds
£m
|
Non-controlling
interest
£m
|
Total
Equity
£m
|
Balance at 1st January 2023
|
19.8
|
88.1
|
17.5
|
(23.4)
|
1,067.0
|
1,169.0
|
0.8
|
1,169.8
|
Profit for the year
|
-
|
-
|
-
|
-
|
183.6
|
183.6
|
0.4
|
184.0
|
Other comprehensive
income/(expense):
|
|
|
|
|
|
|
|
|
Foreign exchange translation and
net investment hedges loss
|
-
|
-
|
(77.9)
|
-
|
-
|
(77.9)
|
-
|
(77.9)
|
Remeasurement loss on
post-retirement benefits
|
-
|
-
|
-
|
-
|
(3.8)
|
(3.8)
|
-
|
(3.8)
|
Deferred tax on remeasurement loss
on post-retirement benefits
|
-
|
-
|
-
|
-
|
1.1
|
1.1
|
-
|
1.1
|
Gain on cash flow hedges net of
tax*
|
-
|
-
|
-
|
5.0
|
-
|
5.0
|
-
|
5.0
|
Total other comprehensive
income/(expense) for the year
|
-
|
-
|
(77.9)
|
5.0
|
(2.7)
|
(75.6)
|
-
|
(75.6)
|
Total comprehensive income/(expense) for the
year
|
-
|
-
|
(77.9)
|
5.0
|
180.9
|
108.0
|
0.4
|
108.4
|
Contributions by and distributions
to owners of the Company:
|
|
|
|
|
|
|
|
|
Dividends paid
|
-
|
-
|
-
|
-
|
(114.5)
|
(114.5)
|
(0.4)
|
(114.9)
|
Equity settled share plans net of
tax
|
-
|
-
|
-
|
-
|
(13.1)
|
(13.1)
|
-
|
(13.1)
|
Issue of share capital
|
-
|
2.0
|
-
|
-
|
-
|
2.0
|
-
|
2.0
|
Employee Benefit Trust
shares
|
-
|
-
|
-
|
5.5
|
-
|
5.5
|
-
|
5.5
|
Balance at 31st December 2023
|
19.8
|
90.1
|
(60.4)
|
(12.9)
|
1,120.3
|
1,156.9
|
0.8
|
1,157.7
|
* During the year, there has been
a reclassification in relation to prior year deferred tax on cash
flow hedges of £0.9m.
Other reserves represent the
Group's cash flow hedges, capital redemption and Employee Benefit
Trust reserves. The non-controlling
interest is a 2.5% share of Spirax Sarco (Korea) Ltd held by
employee shareholders.
Spirax-Sarco Engineering
plc
CONSOLIDATED
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31ST DECEMBER
2022
|
Share
Capital
£m
|
Share
Premium
Account
£m
|
Translation
reserve
£m
|
Other
reserves
£m
|
Retained
Earnings
£m
|
Equity shareholders'
funds
£m
|
Non-controlling
interest
£m
|
Total
Equity
£m
|
Balance at 1st January 2022
|
19.8
|
86.3
|
(40.5)
|
(17.7)
|
961.1
|
1,009.0
|
1.0
|
1,010.0
|
Profit for the year
|
-
|
-
|
-
|
-
|
224.7
|
224.7
|
0.3
|
225.0
|
Other comprehensive
income/(expense):
|
|
|
|
|
|
|
|
|
Foreign exchange translation and
net investment hedges gain
|
-
|
-
|
54.8
|
-
|
-
|
54.8
|
-
|
54.8
|
Transfer to Consolidated Income
Statement of cumulative translation differences on disposal of
subsidiaries
|
-
|
-
|
3.2
|
-
|
-
|
3.2
|
-
|
3.2
|
Remeasurement loss on
post-retirement benefits
|
-
|
-
|
-
|
-
|
(8.3)
|
(8.3)
|
-
|
(8.3)
|
Deferred tax on remeasurement loss
on post-retirement benefits
|
-
|
-
|
-
|
-
|
1.8
|
1.8
|
-
|
1.8
|
Loss on cash flow hedges net of
tax
|
-
|
-
|
-
|
(3.5)
|
-
|
(3.5)
|
-
|
(3.5)
|
Total other comprehensive
income/(expense) for the year
|
-
|
-
|
58.0
|
(3.5)
|
(6.5)
|
48.0
|
-
|
48.0
|
Total comprehensive income/(expense) for the
year
|
-
|
-
|
58.0
|
(3.5)
|
218.2
|
272.7
|
0.3
|
273.0
|
Contributions by and distributions
to owners of the Company:
|
|
|
|
|
|
|
|
|
Dividends paid
|
-
|
-
|
-
|
-
|
(103.1)
|
(103.1)
|
(0.5)
|
(103.6)
|
Equity settled share plans net of
tax
|
-
|
-
|
-
|
-
|
(9.2)
|
(9.2)
|
-
|
(9.2)
|
Issue of share capital
|
-
|
1.8
|
-
|
-
|
-
|
1.8
|
-
|
1.8
|
Employee Benefit Trust
shares
|
-
|
-
|
-
|
(2.2)
|
-
|
(2.2)
|
-
|
(2.2)
|
Balance at 31st December 2022
|
19.8
|
88.1
|
17.5
|
(23.4)
|
1,067.0
|
1,169.0
|
0.8
|
1,169.8
|
Spirax-Sarco Engineering
plc
CONSOLIDATED
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST DECEMBER
2023
|
Notes
|
2023
£m
|
2022
£m
|
Cash flows from operating activities
|
|
|
|
Profit before taxation
|
|
244.5
|
308.1
|
Depreciation, amortisation and
impairment
|
|
112.7
|
81.0
|
Loss/(profit) on disposal of
property, plant and equipment
|
|
0.1
|
(1.4)
|
Cash payments to the pension
schemes greater than the charge to operating profit
|
|
(5.7)
|
(5.3)
|
(Profit)/loss on disposal of
subsidiaries/associates
|
|
(0.4)
|
7.0
|
Acquisition related
costs
|
|
4.3
|
3.8
|
Restructuring related provisions
and current asset impairments
|
|
(3.0)
|
10.2
|
Equity settled share
plans
|
|
6.1
|
8.9
|
Net financing expense
|
|
39.9
|
10.7
|
Operating cash flow before changes in working capital and
provisions
|
|
398.5
|
423.0
|
Decrease/(increase) in trade and
other receivables
|
|
12.6
|
(56.3)
|
(Increase)/decrease in
inventories
|
|
(13.1)
|
(58.3)
|
Increase/(decrease) in
provisions
|
|
2.9
|
(0.8)
|
(Decrease)/increase in trade and
other payables
|
|
(11.6)
|
23.5
|
Cash generated from operations
|
|
389.3
|
331.1
|
Income taxes paid
|
|
(90.7)
|
(90.0)
|
Net cash from operating activities
|
|
298.6
|
241.1
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
Purchase of property, plant and
equipment
|
|
(84.0)
|
(104.3)
|
Proceeds from sale of property,
plant and equipment
|
|
3.1
|
4.0
|
Purchase of software and other
intangibles
|
|
(14.2)
|
(8.9)
|
Development expenditure
capitalised
|
|
(7.2)
|
(4.3)
|
Disposal of businesses
|
|
0.5
|
(2.8)
|
Acquisition of businesses net of
cash acquired
|
8
|
(5.2)
|
(460.3)
|
Interest received
|
3
|
11.3
|
5.6
|
Net cash used in investing activities
|
|
(95.7)
|
(571.0)
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
Proceeds from issue of share
capital
|
|
2.0
|
1.8
|
Employee Benefit Trust share
purchase
|
|
(12.8)
|
(20.8)
|
Repaid borrowings
|
7
|
(221.1)
|
(511.1)
|
New borrowings
|
7
|
192.8
|
1,008.8
|
Interest paid including interest
on lease liabilities
|
3
|
(49.1)
|
(15.5)
|
Repayment of lease
liabilities
|
7
|
(16.1)
|
(12.9)
|
Dividends paid (including
minorities)
|
6
|
(114.9)
|
(103.6)
|
Net cash used in financing activities
|
|
(219.2)
|
346.7
|
|
|
|
|
Net change in cash and cash equivalents
|
7
|
(16.3)
|
16.8
|
Net cash and cash equivalents at
beginning of the year
|
|
243.8
|
219.0
|
Exchange movement
|
7
|
(14.7)
|
8.0
|
Net cash and cash equivalents at end of the
year
|
7
|
212.8
|
243.8
|
Borrowings
|
7
|
(879.5)
|
(934.2)
|
Net debt at end of the year
|
7
|
(666.7)
|
(690.4)
|
Lease liabilities
|
7
|
(96.7)
|
(65.2)
|
Net debt including lease liabilities at end of the
year
|
7
|
(763.4)
|
(755.6)
|
NOTES TO THE FINANCIAL STATEMENTS
1. BASIS OF PREPARATION
The Consolidated Financial
Statements have been prepared in accordance with International
Financial Reporting Standards (IFRS) adopted for use in the United
Kingdom (UK) and therefore comply with those parts of the Companies
Act 2006 that are applicable to companies reporting under
IFRS. IFRS includes the standards and interpretations
approved by the International Accounting Standards Board (IASB)
including International Accounting Standards (IAS) and
interpretations issued by the IFRS Interpretations Committee
(IFRIC).
The financial information included
in this News Release does not constitute statutory accounts of the
Group for the years ended 31st December 2023 and 2022, although it
is derived from those accounts. Statutory accounts for the
year ended 31st December 2022 have been reported on by the Group's
auditor and delivered to the Registrar of Companies.
Statutory accounts for the year ended 31st December 2023 have been
audited and will be delivered to the Registrar of Companies
following the Company's Annual General Meeting. The report of
the auditors for both years was (i) unqualified, (ii) did not
include a reference to any matters to which the auditors drew
attention by way of emphasis without qualifying their report, and
(iii) did not contain a statement under Section 498 (2) or (3) of
the Companies Act 2006.
If approved at the Annual General
Meeting on 15th May 2024, the final dividend will be paid on
24th May 2024 to shareholders on the
register at 26th April 2024. No scrip alternative to the cash
dividends is being offered.
Copies of the Annual Report will
be sent on 28th March 2024 to shareholders who have requested a
hard copy and can be obtained from our office at Charlton House,
Charlton Kings, Cheltenham, GL53 8ER. The Report will also be
available on our website at www.spiraxgroup.com.
As outlined below, there have been
no significant changes in accounting policies from those set out in
the Spirax-Sarco Engineering plc 2022 Annual Report. The
accounting policies have been applied consistently throughout the
years ended 31st December 2022 and 31st December 2023.
NEW STANDARDS AND INTERPRETATIONS ADOPTED IN THE CURRENT
YEAR
During the current year, the Group
has applied the following amendments to IFRS Standards and
Interpretations issued by the International Accounting Standards
Board (IASB) effective for annual periods that begin on or after
1st January 2023. Adoption has not had a material impact on
the disclosures or on the amounts reported in these Financial
Statements:
●
|
IFRS 17 Insurance
Contracts
|
●
|
Amendments to IAS 1 Presentation
of Financial Statements and IFRS Practice Statement 2 Making
Materiality Judgements- Disclosure of Accounting
Policies
|
●
|
Amendments to IAS 12 Income
Taxes-Deferred Tax related to Assets and Liabilities arising from a
Single Transaction
|
●
|
Amendments to IAS 12 Income Taxes-
International Tax Reform-Pillar Two Model Rules and
|
●
|
Amendments to IAS 8 Accounting
Policies, Changes in Accounting Estimates and Errors-Definition of
Accounting Estimates
|
The economies in Argentina and
Turkey are subject to high inflation. IAS 29 (Financial
Reporting in Hyperinflationary Economies) requires the following
application:
(i) adjustment of historical cost
non-monetary assets and liabilities for the change in purchasing
power caused by inflation from the date of initial recognition to
the balance sheet date
(ii) adjustment of the
Consolidated Income Statement for inflation during the period
and
(iii) translation of the
Consolidated Income Statement at the period-end foreign exchange
rate instead of an average rate
At 31st December 2023 the Group
has performed a review of the impact of the application of IAS 29
and concluded that the adoption of IAS 29 is not required as its
impact on the Consolidated Financial Statements is not
material. The Group will continue to monitor and assess this
position going forward.
NEW STANDARDS AND INTERPRETATIONS NOT YET
APPLIED
At the date of authorisation of
these Financial Statements, the Group has not applied the following
new and revised IFRS Standards that have been issued but are not
yet effective:
●
|
Amendments to IFRS 10 and IAS 28:
Sale or Contribution of Assets between an Investor and its
Associate or Joint Venture
|
●
|
Amendments to IAS 1:
Classification of liabilities as Current or Non-current
|
●
|
Amendments to IAS 1: Non-current
Liabilities with Covenants
|
●
|
Amendments to IAS 7 and IFRS 7:
Supplier Finance Arrangements and
|
●
|
Amendments to IFRS 16: Lease
Liability in a Sale and Leaseback
|
The Directors do not expect that
the adoption of the Standards listed above will have a material
impact on the Financial Statements of the Group in future
periods.
GOING CONCERN
In determining the basis of
preparation for the Consolidated Financial Statements, the
Directors have considered the Group's available resources, current
business activities and factors likely to impact on its future
development and performance, which are described in the Chief
Executive Officer's Review, Operating Review and Financial
Review.
The Group's principal objective
when managing liquidity is to safeguard the Group's ability to
continue as a going concern for at least 12 months from the date of
signing the 2023 Annual Report. The Group retains sufficient
resources to remain in compliance with all the required terms and
conditions within its borrowing facilities with material headroom
and no material uncertainties have been identified. The Group
continues to conduct ongoing risk assessments on its business
operations and liquidity.
Consideration has also been given
to reverse stress tests, which seek to identify factors that might
cause the Group to require additional liquidity and form a view as
to the probability of these occurring. The Group's financial
position remains robust, with the next maturity of our committed
debt facilities being US$150m million of Bank Term loans which
mature in October 2025 and which are accounted for within the cash
flow forecast. The Group's debt facilities contain a leverage
covenant of up to 3.5x. Certain debt facilities also contain
an interest cover covenant of a minimum of 3.0x. The Group
regularly monitors its financial position to ensure that it remains
within the terms of these debt covenants. At 31st December
2023 leverage (net debt excluding lease liabilities divided by
adjusted earnings before interest, tax, depreciation and
amortisation) was 1.7x (2022: 1.7x), interest cover (adjusted
earnings before interest, tax, depreciation and amortisation
divided by net bank interest) was 10x (2022: 58x).
Reverse 'stress testing' was also
performed to assess what level of business underperformance would
be required for a breach of the financial covenants to occur, the
results of which evidenced that no reasonably possible change in
future forecast cash flows would cause a breach of these
covenants. In addition, the reverse stress test does not take
into account any mitigating actions which the Group would implement
in the event of a severe and extended revenue and profitability
decline. Such actions would serve to further increase
covenant headroom.
Following this assessment, the
Board of Directors are satisfied that the Group has sufficient
resources to continue in operation for the foreseeable future, a
period of not less than 12 months from the date of this
report. Accordingly, they continue to adopt the going concern
basis in relation to this conclusion and preparing the Consolidated
Financial Statements.
2. SEGMENTAL REPORTING
As required by IFRS 8 Operating
Segments, the segmental structure reflects the current internal
reporting provided to the Chief Operating Decision Maker
(considered to be the Board) on a regular basis to assist in making
decisions on resource allocation to each segment and to assess
performance.
The Group is organised into three
segments with the following core product expertise:
●
|
Steam Thermal Solutions -
Industrial and commercial steam systems
|
●
|
Electric Thermal Solutions -
Electrical process heating and temperature management
solutions
|
●
|
Watson-Marlow Fluid Technology
Solutions - Peristaltic and niche pumps and associated fluid path
technologies
|
No changes to the structure of
operating segments have been made during the current
period.
Analysis by operating segment
2023
|
Revenue
£m
|
Total
operating
profit
£m
|
Operating
profit
margin
%
|
Steam Thermal Solutions
|
910.1
|
205.2
|
22.5%
|
Electric Thermal
Solutions
|
378.5
|
25.8
|
6.8%
|
Watson-Marlow
|
394.0
|
81.2
|
20.6%
|
Corporate
|
-
|
(27.8)
|
|
Total
|
1,682.6
|
284.4
|
16.9%
|
|
|
|
|
Net finance expense
|
|
(39.9)
|
|
Profit before taxation
|
|
244.5
|
|
|
|
|
|
2022
|
Revenue
£m
|
Total
operating
profit
£m
|
Operating
profit
margin
%
|
Steam Thermal Solutions
|
866.0
|
196.2
|
22.7%
|
Electric Thermal
Solutions
|
256.1
|
7.3
|
2.9%
|
Watson-Marlow
|
488.5
|
154.4
|
31.6%
|
Corporate
|
|
(39.1)
|
|
Total
|
1,610.6
|
318.8
|
19.8%
|
|
|
|
|
Net finance expense
|
|
(10.7)
|
|
Profit before taxation
|
|
308.1
|
|
The following table details the
split of revenue by geography for the combined Group:
|
2023
£m
|
2022
£m
|
Europe, Middle East and
Africa
|
718.7
|
649.6
|
Asia Pacific
|
357.4
|
384.3
|
Americas
|
606.5
|
576.7
|
Total revenue
|
1,682.6
|
1,610.6
|
|
|
|
Revenue generated by Group
companies based in the USA is £454.2m (2022: £433.0m), in China is
£177.8m (2022: £213.2m), in Germany is £153.2m (2022: £134.3m), in
the UK is £110.0m (2022: £115.7m) and the rest of the
world is £787.4m (2022: £714.4m).
Net financing income and expense
|
|
2023
|
|
|
2022
|
|
|
Income
£m
|
Expense
£m
|
Net
£m
|
Income
£m
|
Expense
£m
|
Net
£m
|
Steam Thermal Solutions
|
4.1
|
(3.3)
|
0.8
|
3.6
|
(1.8)
|
1.8
|
Electric Thermal
Solutions
|
0.8
|
(1.6)
|
(0.8)
|
0.3
|
(0.5)
|
(0.2)
|
Watson-Marlow
|
0.9
|
(1.2)
|
(0.3)
|
0.3
|
(0.6)
|
(0.3)
|
Corporate
|
5.5
|
(45.1)
|
(39.6)
|
1.4
|
(13.4)
|
(12.0)
|
Total net financing expense
|
11.3
|
(51.2)
|
(39.9)
|
5.6
|
(16.3)
|
(10.7)
|
Net
assets
|
2023
|
2022
|
|
Assets
£m
|
Liabilities
£m
|
Assets
£m
|
Liabilities
£m
|
Steam Thermal Solutions
|
714.1
|
(203.7)
|
756.8
|
(219.2)
|
Electric Thermal
Solutions
|
1,128.8
|
(82.7)
|
1,171.9
|
(80.2)
|
Watson-Marlow
|
429.3
|
43.6)
|
423.8
|
(55.3)
|
Corporate*
|
31.9
|
(1.1)
|
15.5
|
(7.4)
|
|
2,304.1
|
(331.1)
|
2,368.0
|
(362.1)
|
Liabilities
|
(331.1)
|
|
(362.1)
|
|
Net deferred tax
|
(37.2)
|
|
(59.1)
|
|
Net tax payable
|
(14.7)
|
|
(21.4)
|
|
Net debt including lease
liabilities
|
(763.4)
|
|
(755.6)
|
|
Net assets
|
1,157.7
|
|
1,169.8
|
|
|
|
|
|
| |
* In
order to align with how we manage net assets across the Group, we
have reallocated specific assets and liabilities to the corporate
operating segment in both the current and the comparative
periods.
Non-current assets in the USA were
£689.1m (2022: £686.8m), in France were £388.7m (2022: £403.1m), in
the UK were £251.1m (2022: £284.1m), in Germany were £161.0m (2022:
£165.6m) and in the rest of the world were £193.7m (2022:
191.8m).
Capital additions, depreciation, amortisation and
impairment
|
2023
|
2022
|
|
Capital
additions
£m
|
Depreciation, amortisation
and impairment
£m
|
Capital
additions
£m
|
Depreciation, amortisation
and impairment
£m
|
Steam Thermal Solutions
|
48.2
|
47.9
|
43.8
|
32.9
|
Electric Thermal
Solutions
|
32.2
|
40.3
|
285.4
|
24.7
|
Watson-Marlow
|
66.6
|
24.5
|
76.4
|
19.0
|
Corporate
|
14.1
|
-
|
3.3
|
4.4
|
Total
|
161.1
|
112.7
|
408.9
|
81.0
|
Capital additions include
property, plant and equipment of £84.0m (2022: £135.0m) and
intangible assets of £25.0m (2022: £258.3m). Right-of-use
asset additions of £52.1m (2022: £15.6m) occurred during the
12-month period to 31st December 2023. Capital additions
split between the USA £68.7m (2022: £186.4m), UK £43.6m (2022:
£51.8m) and rest of world £48.8m (2022: £170.7m).
3. NET FINANCING INCOME AND EXPENSE
|
2023
£m
|
2022
£m
|
Financial expenses:
|
|
|
Bank and other borrowing interest
payable
|
(46.9)
|
(14.0)
|
Interest expense on lease
liabilities
|
(2.2)
|
(1.5)
|
Net interest on pension scheme
liabilities
|
(2.1)
|
(0.7)
|
|
(51.2)
|
(16.3)
|
Financial income:
|
|
|
Bank interest
receivable
|
11.3
|
5.6
|
Net financing expense
|
(39.9)
|
(10.7)
|
|
|
|
Net bank interest
|
(35.6)
|
(8.4)
|
Interest expense on lease
liabilities
|
(2.2)
|
(1.5)
|
Net interest on pension scheme
liabilities
|
(2.1)
|
(0.8)
|
Net financing expense
|
(39.9)
|
(10.7)
|
4. TAXATION
Analysis of charge in the
year
|
2023
£m
|
2022
£m
|
UK corporation tax:
|
|
|
Current tax on income for the
year
|
9.4
|
7.1
|
Adjustments in respect of prior
years
|
(0.1)
|
(0.7)
|
|
9.3
|
6.4
|
Foreign tax:
|
|
|
Current tax on income for the
year
|
75.3
|
88.6
|
Adjustments in respect of prior
years
|
(0.7)
|
(1.3)
|
|
74.6
|
87.3
|
|
|
|
Total current tax
charge
|
83.9
|
93.7
|
Deferred tax - UK
|
(10.7)
|
(1.1)
|
Deferred tax - Foreign
|
(12.7)
|
(9.5)
|
Tax on profit on ordinary activities
|
60.5
|
83.1
|
The Group's tax charge in future
years will be affected by the proportion of profits arising and the
effective tax rates in the various territories in which the Group
operates. The rate may also be affected by the impact of any
acquisitions.
The Group is subject to a tax
adjustment in Argentina that seeks to offset the impact of
inflation upon taxable profits. Given the current high levels
of inflation in Argentina, this has a meaningful impact on the
Group's tax charge. The adjustment gave a reduction in the
Group's effective tax rate in the year of 260 bps being £6.4m on a
statutory basis (2022: 180 bps being £5.5m). Whilst we
include the expected impact of this adjustment in our guidance for
the effective tax rate, this is difficult to accurately forecast
given the current volatility of Argentinian inflation.
The Group monitors income tax
developments in the territories in which it operates. On 14th
July 2023, the government of the United Kingdom, where the Group's
parent company is incorporated, enacted the Pillar Two income taxes
legislation effective from 1st January 2024. Under the
legislation, the parent company will be required to pay top-up tax
on profits of its subsidiaries that are taxed at an effective tax
rate of less than 15%. The main jurisdiction where this
initiative may impact is Argentina. As noted above, given the
volatility of Argentinian inflation it is difficult to accurately
forecast the impact that this Base Erosion and Profit Shifting
(BEPS) initiative will have on the Group's tax charge. The
Group is continuing to assess the impact of the Pillar Two income
taxes legislation on its future financial performance. The
Group has applied the temporary exception issued by the IASB in May
2023 from the accounting requirements for deferred taxes in IAS 12.
Accordingly, the Group neither recognises nor discloses
information about deferred tax assets and liabilities related to
Pillar Two income taxes.
In October 2017, the European
Commission (EC) opened a State Aid investigation into the UK's
Controlled Foreign Company (CFC) regime. In April 2019, the
EC published its final decision that the UK CFC Finance Company
Exemption (FCE) constituted State Aid in certain circumstances,
following which the UK Government appealed the decision to the EU
General Court. In June 2022, the EU General Court dismissed
the UK Government's appeal following which the UK Government lodged
a further appeal to the European Court of Justice. The UK
Government's appeal has been heard but no decision has been
released. Like other UK Groups, the Group submitted its own appeal
against the EC's decision.
The Group's benefit from the FCE
in the period from 1st January 2013 to 31st December 2023 is
approximately £8.9m, including compound interest. To date,
the Group has received, paid, and appealed Charging Notices
totalling £4.9m, assessed for the period from 1st January 2017 to
31st December 2018. The Group expects to recover this in the event
of a successful appeal and has recognised a receivable for the full
amount at the year end balance sheet date as non-current asset.
The Group has not recognised a receivable for any repayment
interest, estimated at £0.2m, on the amount of £4.9m. The
Group has not received a Charging Notice for the period prior to
1st January 2017, the benefit for this period being £2.9m.
HMRC has enquired into the benefit received during 2019,
which the Group estimates to be £1.1m. No provisions have
been recognised at the year end balance sheet date for either the
Charging Notice amounts or for the estimates for the other
periods.
5. EARNINGS PER SHARE
|
2023
|
2022
|
Profit attributable to equity
shareholders (£m)
|
183.6
|
224.7
|
Weighted average shares
(million)
|
73.6
|
73.6
|
Dilution (million)
|
0.2
|
0.2
|
Diluted weighted average shares
(million)
|
73.8
|
73.8
|
Basic earnings per share
|
249.5p
|
305.1p
|
Diluted earnings per share
|
248.9p
|
304.4p
|
Basic and diluted earnings per
share calculated on an adjusted profit basis are included in the
Appendix. The dilution is in respect of the Performance Share
Plan.
6. DIVIDENDS
|
2023
£m
|
2022
£m
|
Amounts paid in the
year:
|
|
|
Final dividend for the year ended
31st December 2022 of 109.5p (2021: 97.5p) per share
|
80.7
|
71.9
|
Interim dividend for the year
ended 31st December 2023 of 46.0p (2022: 42.5p) per
share
|
33.8
|
31.2
|
Total dividends paid
|
114.5
|
103.1
|
Amounts arising in respect of the
year:
|
|
|
Interim dividend for the year
ended 31st December 2023 of 46.0p (2022: 42.5p) per
share
|
33.8
|
31.2
|
Proposed final dividend for the
year ended 31st December 2023 of 114.0p (2022: 109.5p) per
share
|
84.0
|
80.8
|
Total dividends arising
|
117.8
|
112.0
|
7. ANALYSIS OF CHANGES IN NET DEBT, INCLUDING CHANGES IN
LIABILITIES ARISING FROM FINANCING ACTIVITIES
2023
|
At
1st
Jan
2023
£m
|
Cash
flow
£m
|
Acquired
debt*
£m
|
Exchange
movement
£m
|
At
31st Dec
2023
£m
|
Current portion of long-term
borrowings
|
(202.9)
|
|
|
|
(3.6)
|
Non-current portion of long-term
borrowings
|
(731.3)
|
|
|
|
(875.9)
|
Total borrowings
|
(934.2)
|
|
|
|
(879.5)
|
|
|
|
|
|
|
Lease Liabilities
|
(65.2)
|
16.1
|
(49.9)
|
2.3
|
(96.7)
|
Borrowings
|
(934.2)
|
28.3
|
-
|
26.4
|
(879.5)
|
Changes in liabilities arising from
financing
|
(999.4)
|
44.4
|
(49.9)
|
28.7
|
(976.2)
|
Cash at bank
|
328.9
|
46.5
|
-
|
(15.7)
|
359.7
|
Bank overdrafts
|
(85.1)
|
(62.8)
|
-
|
1.0
|
(146.9)
|
Net cash and cash equivalents
|
243.8
|
(16.3)
|
-
|
(14.7)
|
212.8
|
Net debt and lease liabilities
|
(755.6)
|
28.1
|
(49.9)
|
14.0
|
(763.4)
|
Net debt including lease liabilities
|
(690.4)
|
12.0
|
-
|
11.7
|
(666.7)
|
*
Debt acquired includes both debt acquired due to acquisition, and
debt recognised on the balance sheet due to entry into new leases
and disposal of existing leases.
The net cashflow from borrowings
of £28.3m consists of £192.8m of new borrowings and £221.1m of
repaid borrowings.
During the year £46.9m of interest
on external borrowings (2022: £14.0m) was incurred and
paid.
At 31st December 2023 total lease
liabilities consist of £14.5m (2022: £14.1m) short-term and £82.2m
(2022: £51.1m) long-term.
2022
|
At
1st
Jan
2022
£m
|
Cash
flow
£m
|
Acquired
debt*
£m
|
Disposal of
subsidiaries
£m
|
Exchange
movement
£m
|
At
31st Dec
2022
£m
|
Current portion of long-term
borrowings
|
(59.6)
|
|
|
|
|
(202.9)
|
Non-current portion of long-term
borrowings
|
(289.9)
|
|
|
|
|
(731.3)
|
Total borrowings
|
(349.5)
|
|
|
|
|
(934.2)
|
|
|
|
|
|
|
|
Lease Liabilities
|
(60.1)
|
12.9
|
(15.2)
|
-
|
(2.8)
|
(65.2)
|
Borrowings
|
(349.5)
|
(497.7)
|
(67.0)
|
-
|
(20.0)
|
(934.2)
|
Changes in liabilities arising from
financing
|
(409.6)
|
(484.8)
|
(82.2)
|
-
|
(22.8)
|
(999.4)
|
Cash at bank
|
274.6
|
46.3
|
-
|
(2.8)
|
10.8
|
328.9
|
Bank overdrafts
|
(55.6)
|
(26.7)
|
-
|
-
|
(2.8)
|
(85.1)
|
Net cash and cash equivalents
|
219.0
|
19.6
|
-
|
(2.8)
|
8.0
|
243.8
|
Net debt and lease liabilities
|
(190.6)
|
(465.2)
|
(82.2)
|
(2.8)
|
(14.8)
|
(755.6)
|
Net debt excluding lease liabilities
|
(130.5)
|
(478.1)
|
(67.0)
|
(2.8)
|
(12.0)
|
(690.4)
|
8. PURCHASE OF BUSINESSES
During the period, the Group
acquired distributors resulting in a total cash outflow of £5.2m
and creating acquired intangibles of £3.6m. Additionally,
during the period the fair value of the assets acquired as part of
the acquisitions of Vulcanic (and its related companies) and Durex
Industries were reassessed, leading to an immaterial decrease in
goodwill for Durex Industries and an offsetting immaterial increase
in goodwill for Vulcanic.
9.
RESPONSIBILITY statement OF THE DIRECTORS ON
THE ANNUAL REPORT
The Responsibility Statement below
has been prepared in connection with the Company's full Annual
Report for the year ending 31st December 2023. Certain parts
thereof are not included within this announcement.
We confirm to the best of our
knowledge:
●
|
the Financial Statements, prepared
in accordance with IFRS as adopted by the UK, give a true and fair
view of the assets, liabilities, financial position and profit and
loss of the Company and the undertakings included in the
consolidation taken as a whole
|
●
|
the Strategic Report includes a
fair review of the development and performance of the business and
the position of the Company and the undertakings included in the
consolidation taken as a whole, together with a description of the
Principal Risks and uncertainties they face
|
●
|
the Annual Report and Financial
Statements, taken as a whole, are fair, balanced and understandable
and provide the information necessary to assess the Company's
performance, business model and strategy
|
This Responsibility Statement was
approved by the Board of Directors on 6th March 2024 and is signed
on its behalf by:
N.B. Patel, Group Chief Executive
Officer
10. Cautionary
statement
All statements other than
statements of historical fact included in this document, including,
without limitation, those regarding the financial condition,
results, operations and businesses of Spirax-Sarco Engineering plc
and its strategy, plans and objectives and the markets and
economies in which it operates, are forward-looking
statements. These forward-looking statements which reflect
management's assumptions made on the basis of information available
to it at this time, involve known and unknown risks, uncertainties
and other important factors which could cause the actual results,
performance or achievements of Spirax-Sarco Engineering plc or the
markets and economies in which we operate to be materially
different from future results, performance or achievements
expressed or implied by such forward-looking statements.
Spirax-Sarco Engineering plc and its Directors accept no liability
to third parties in respect of this report save as would arise
under English law. Accordingly, any liability to a person who
has demonstrated reliance on any untrue or misleading statement or
omission shall be determined in accordance with schedule 10A of the
Financial Services and Markets Act 2000. It should be noted
that schedule 10A contains limits on the liability of the Directors
of Spirax-Sarco Engineering plc so that their liability is solely
to Spirax-Sarco Engineering plc.
11. EXCHANGE RATE IMPACTS
Whilst not an IFRS disclosure or
part of the audited accounts, set out below is an additional
disclosure that highlights the movements in a selection of exchange
rates between 2023 and 2022. Exchange
rates to sterling have been as follows:
|
Average
2023
|
Average
2022
|
Change
%
|
Closing
2023
|
Closing
2022
|
Change%
|
US dollar
|
1.24
|
1.24
|
+0%
|
1.27
|
1.21
|
-5%
|
Euro
|
1.15
|
1.17
|
+2%
|
1.15
|
1.13
|
-2%
|
Chinese renminbi
|
8.80
|
8.32
|
-6%
|
9.03
|
8.34
|
-8%
|
Korean won
|
1,626
|
1,587
|
-2%
|
1,648
|
1,525
|
-8%
|
Brazilian real
|
6.22
|
6.41
|
+3%
|
6.18
|
6.39
|
+3%
|
Argentine peso
|
383
|
162
|
-136%
|
1,029
|
214
|
-381%
|
|
|
|
|
|
|
|
A negative movement indicates a
strengthening in sterling versus that currency. When sterling
strengthens against other currencies in which the Group operates,
the Group incurs a loss on translation of the financial results
into sterling. On a translation basis, sales decreased
by 1.7% and adjusted operating profit decreased by 3.4%, while
transactional currency impacts increased profit by 1.6%, giving a
total decrease to profit from currency movements of
1.9%.
Appendix - Alternative performance measures
The Group reports under IFRS and
also uses alternative performance measures where the Board believe
that they help to effectively monitor the performance of the Group
and users of the Financial Statements might find them
informative. Certain alternative performance measures also
form a meaningful element of Executive Directors'
variable remuneration. Net debt to EBITDA is also a covenant
assessed for external borrowing purposes. A definition of the
alternative performance measures is included in the Annual Report
and a reconciliation to the closest IFRS equivalent are disclosed
below. The term 'adjusted' is not defined under IFRS and may
therefore not be comparable with similarly titled measures reported
by other companies. Adjusted performance measures are not
considered to be a substitute for, or superior to, IFRS
measures.
Adjusted operating profit
Adjusted operating profit excludes
items that are considered to be significant in nature and/or
quantum at either a Group or an operating segment level and where
treatment as an adjusted item provides stakeholders with additional
useful information to assess the period-on-period trading
performance of the Group. The Group excludes such items
including those defined as follows:
●
|
Amortisation and impairment of
acquisition-related intangible assets
|
●
|
Costs associated with the
acquisition or disposal of businesses
|
●
|
Gain or loss on disposal of a
subsidiary and/or disposal groups
|
●
|
Reversal of acquisition-related
fair value adjustments to inventory
|
●
|
Changes in deferred and contingent
consideration payable on acquisitions
|
●
|
Costs associated with a material
restructuring programme
|
●
|
Material gains or losses on
disposal of property
|
●
|
Accelerated depreciation,
impairment and other related costs on non-recurring, material
property redevelopments
|
●
|
Material non-recurring pension
costs or credits
|
●
|
Costs or credits arising from
regulatory and litigation matters
|
●
|
Other material items which are
considered to be non-recurring in nature and/or are not a result of
the underlying trading of the business
|
●
|
Related tax effect on adjusting
items above and other tax items which do not form part of the
underlying tax rate
|
A reconciliation between operating
profit as reported under IFRS and adjusted operating profit is
given below.
|
2023
£m
|
2022
£m
|
Operating profit as reported under IFRS
|
284.4
|
318.8
|
Amortisation of
acquisition-related intangible assets
|
37.2
|
23.7
|
Software related
impairment
|
13.9
|
-
|
Acquisition-related
items
|
5.7
|
9.1
|
Restructuring costs
|
5.2
|
15.5
|
Asset related
impairment
|
1.8
|
-
|
Reversal of acquisition-related
fair value adjustments to inventory
|
1.3
|
1.8
|
Disposal of associate
|
(0.4)
|
-
|
Disposal of subsidiaries in
Russia
|
-
|
7.1
|
Accelerated depreciation and other
related costs on one-off property redevelopments
|
-
|
4.2
|
Total adjusting items
|
64.7
|
61.4
|
Adjusted operating profit
|
349.1
|
380.2
|
Tax on adjusting items
|
2023
|
2022
|
|
Adjusted
£m
|
Adj't £m
|
Total
£m
|
Adjusted
£m
|
Adj't £m
|
Total £m
|
UK Corporation tax
|
9.3
|
-
|
9.3
|
6.6
|
(0.2)
|
6.4
|
Foreign tax
|
80.7
|
(6.1)
|
74.6
|
88.1
|
(0.8)
|
87.3
|
Deferred tax
|
(11.2)
|
(12.2)
|
(23.4)
|
(2.2)
|
(8.4)
|
(10.6)
|
Total taxation
|
78.8
|
(18.3)
|
60.5
|
92.5
|
(9.4)
|
83.1
|
Effective tax rate
|
25.5%
|
28.3%
|
24.7%
|
25.0%
|
15.0%
|
27.0%
|
Adjusted earnings per share
|
2023
|
2022
|
Profit for the year attributable to equity holders as
reported under IFRS (£m)
|
183.6
|
224.7
|
Items excluded from adjusted
profit (£m)
|
64.7
|
62.5
|
Tax effects on adjusted items
(£m)
|
(18.3)
|
(9.4)
|
Adjusted profit for the year attributable to equity holders
(£m)
|
230.0
|
277.8
|
Weighted average shares
(million)
|
73.6
|
73.6
|
Basic adjusted earnings per share
|
312.4p
|
377.2p
|
Diluted weighted average shares
(million)
|
73.8
|
73.8
|
Diluted adjusted earnings per share
|
311.8p
|
376.3p
|
Basic adjusted earnings per share
is defined as adjusted profit for the period attributable to equity
holders divided by the weighted average number of shares in
issue. Diluted adjusted earnings per share is defined as
adjusted profit for the period attributable to equity holders
divided by the diluted weighted average number of
shares.
Basic and diluted EPS calculated
on an IFRS profit basis are included in Note 5.
Dividend Cover
The Group monitors dividend cover
to ensure this remains within the Group's expected range.
Dividend cover is calculated as adjusted earnings per share
divided by dividends per share.
Adjusted cash flow
A reconciliation showing the items
that bridge between net cash from operating activities as reported
under IFRS to an adjusted basis is given below. Adjusted cash
from operations is used by the Board to monitor the performance of
the Group, with a focus on elements of cashflow, such as net
capital expenditure, which are subject to day-to-day control by the
business.
|
2023
£m
|
2022
£m
|
Net cash from operating activities as reported under
IFRS
|
298.6
|
241.1
|
Restructuring and
acquisition-related costs
|
10.8
|
10.2
|
Net capital expenditure excluding
acquired intangibles from acquisitions
|
(102.3)
|
(113.5)
|
Income tax paid
|
90.7
|
90.0
|
Repayments of principal under
lease liabilities
|
(16.1)
|
(12.9)
|
Adjusted cash from operations
|
281.7
|
214.9
|
Adjusted cash conversion in 2023
is 81% (2022: 57%). Cash conversion is calculated as adjusted
cash from operations divided by adjusted operating
profit.
Cash generation
Cash generation is one of the
Group's key performance indicators used by the Board to monitor the
performance of the Group and measure the successful implementation
of our strategy. It is one of two financial measures on which
Executive Directors' variable remuneration is based.
Cash generation is adjusted
operating profit after adding back depreciation and amortisation,
less cash payments to pension schemes in excess of the charge to
adjusted operating profit, equity settled share plans, net capital
expenditure excluding acquired intangibles, working capital changes
and repayment of principal under lease liabilities. Cash
generation is equivalent to adjusted cash from operations, a
reconciliation between this and net cash from operating activities
as reported under IFRS is shown above.
Return on invested capital (ROIC) and return on capital
employed (ROCE)
The Group distinguishes between
invested capital and capital employed when calculating return on
capital. Invested capital represents the total capital
invested in the business and is equal to total equity plus net debt
and therefore includes the impact of acquisitions and
disposals. Capital employed is invested capital less certain
non-current assets and non-current liabilities and therefore
reflects capital that is more operational in nature. Both of
these return metrics are used to ensure a full assessment of
business performance.
Return on invested capital (ROIC)
ROIC measures the post-tax return
on the total capital invested in the Group. It is calculated
as adjusted operating profit after tax divided by average invested
capital. Average invested capital is defined as the average
of the closing balance at the current and prior year
end. Taxation is calculated as
adjusted operating profit multiplied by the adjusted effective tax
rate.
An analysis of the components is
as follows:
|
2023
£m
|
2022
£m
|
Total equity
|
1,157.7
|
1,169.8
|
Net debt including lease
liabilities
|
763.4
|
755.6
|
Total invested capital
|
1,921.1
|
1,925.4
|
Average invested capital
|
1,923.2
|
1,563.0
|
Average invested capital (excluding acquisitions, disposals
and leases)
|
1,336.4
|
1,263.8
|
|
|
|
Operating profit as reported under
IFRS
|
284.4
|
318.8
|
Adjustments (see adjusted
operating profit)
|
64.7
|
61.4
|
Adjusted operating
profit
|
349.1
|
380.2
|
Taxation
|
(89.0)
|
(94.9)
|
Adjusted operating profit after tax
|
260.1
|
285.3
|
Adjusted operating profit after tax (excluding acquisitions,
disposals and leases)
|
236.7
|
277.6
|
|
|
|
Return on invested capital
|
13.5%
|
18.3%
|
Return on invested capital (excluding acquisitions, disposals
and leases)
|
17.7%
|
22.0%
|
Return on capital employed (ROCE)
ROCE measures effective management
of fixed assets and working capital relative to the profitability
of the business. It is calculated as adjusted operating
profit divided by average capital employed. Average capital
employed is defined as the average of the closing balance at the
current and prior year end. More information on ROCE
can be found in the Capital Employed and ROCE sections of the
Financial Review.
An analysis of the components is
as follows:
|
2023
£m
|
2022
£m
|
Property, plant and
equipment
|
415.1
|
384.5
|
Right-of-use assets
|
98.4
|
67.2
|
Software and development
costs
|
42.3
|
44.5
|
Prepayments
|
1.9
|
2.0
|
Inventories
|
285.2
|
290.0
|
Trade receivables
|
299.8
|
341.1
|
Other current assets
|
71.4
|
79.6
|
Tax recoverable
|
13.6
|
19.0
|
Trade, other payables and current
provisions
|
(260.7)
|
(295.0)
|
Current tax payable
|
(28.3)
|
(40.4)
|
Capital employed
|
938.7
|
892.5
|
Average capital employed
|
915.6
|
775.9
|
Average capital employed (excluding acquisitions, disposals
and leases)
|
772.4
|
677.5
|
|
|
|
Operating profit
|
284.4
|
318.8
|
Adjustments (see adjusted
operating profit)
|
64.7
|
61.4
|
Adjusted operating profit
|
349.1
|
380.2
|
Adjusted operating profit (excluding acquisitions, disposals
and leases)
|
317.7
|
369.9
|
Return on capital employed
|
38.1%
|
49.0%
|
Return on capital employed (excluding acquisitions, disposals
and leases)
|
41.1%
|
54.6%
|
A reconciliation of capital
employed to net assets as reported under IFRS and disclosed on the
Consolidated Statement of Financial Position is given
below.
|
2023
£m
|
2022
£m
|
Capital employed
|
938.7
|
892.5
|
Goodwill and acquired
intangibles
|
1,087.0
|
1,159.1
|
Investment in associate
|
3.0
|
-
|
Post-retirement
benefits
|
(51.4)
|
(52.1)
|
Net deferred tax
|
(37.2)
|
(59.1)
|
Non-current provisions and
long-term payables
|
(19.0)
|
(15.0)
|
Lease liabilities
|
(96.7)
|
(65.2)
|
Net debt
|
(666.7)
|
(690.4)
|
Net assets as reported under IFRS
|
1,157.7
|
1,169.8
|
Net debt including lease liabilities
A reconciliation between net debt
and net debt including lease liabilities is given below. A
breakdown of the balances that are included within net debt is
given within Note 7. Net debt excludes lease liabilities to
be consistent with how net debt is defined for external debt
covenant purposes, as well as to enable comparability with prior
years.
|
2023
£m
|
2022
£m
|
Net debt
|
666.7
|
690.4
|
Lease liabilities
|
96.7
|
65.2
|
Net debt including lease liabilities
|
763.4
|
755.6
|
Net debt to earnings before interest, tax, depreciation and
amortisation (EBITDA)
To assess the size of the net debt
balance relative to the size of the earnings for the Group we
analyse net debt as a proportion of EBITDA. EBITDA is
calculated by adding back depreciation and amortisation of owned
property, plant and equipment, software and development to adjusted
operating profit. For half year calculations, this is based
on the results for the last 12 months all translated at the
exchange rate used for the half year period. Net debt is
calculated as cash and cash equivalents less Bank overdrafts,
short-term borrowings and long-term borrowings (excluding
short-term and long-term lease liabilities). The net debt to EBITDA
ratio is calculated as follows:
|
2023
£m
|
2022
£m
|
Adjusted operating
profit
|
349.1
|
380.2
|
Depreciation and amortisation of
property, plant and equipment, software and development
|
44.2
|
37.4
|
Acquisitions and disposals
proforma basis (EBITDA)
|
-
|
33.7
|
EBITDA
|
393.3
|
451.3
|
Net debt
|
666.7
|
690.4
|
Net debt to EBITDA
|
1.7x
|
1.5x
|
The components of net debt are
disclosed in Note 7.
Organic measures
As we are a multi-national Group
of companies, who trade in a large number of foreign currencies and
also acquire and sometimes dispose of companies, we also refer to
organic performance measures throughout the News Release.
These strip out the effects of the movement of foreign currency
exchange rates and of acquisitions and disposals. The Board
believe that this allows users of the accounts to gain a further
understanding of how the Group has performed. Exchange
translation movements are assessed by re-translating prior period
reported values to current period exchange rates. Exchange
transaction impacts on operating profit are assessed on the basis
of transactions being at constant currency between
years.
The incremental impact of any
acquisitions that occurred in either the current period or prior
period is excluded from the organic results of the current period
at current period exchange rates. For any disposals that
occurred in the current or prior period, the current period organic
results include the difference between the current and prior period
financial results only for the like-for-like period of
ownership.
The organic percentage movement is
calculated as the organic movement divided by the prior period at
current period exchange rates, excluding disposals for the non
like-for-like period of ownership. The organic bps change in
adjusted operating profit margin is the difference between the
current period margin, excluding the incremental impact of
acquisitions, and the prior period margin excluding disposals for
the non like-for-like period of ownership at current period
exchange rates.
A reconciliation of the movement
in revenue and adjusted operating profit compared to the prior
period is given below.
|
2022
£m
|
Exchange
£m
|
Organic
£m
|
Acquisitions and
disposal1
£m
|
2023
£m
|
Organic
|
Reported
|
Revenue
|
1,610.6
|
(27.2)
|
(16.0)
|
115.2
|
1,682.6
|
-1%
|
+4%
|
Adjusted operating
profit
|
380.2
|
(7.1)
|
(45.9)
|
21.9
|
349.1
|
-12%
|
-8%
|
Adjusted operating profit
margin
|
23.6%
|
|
|
|
20.7%
|
-270
bps
|
-290
bps
|
1 Results include the
impact of (i) the acquisition of Vulcanic and Durex Industries and
(ii) the treatment of our Russian operating companies as
disposals from the date at which
the Group suspended all trading with and within Russia.
Proforma Revenue
Due to the disposal of our Russian
operating companies and the acquisitions of Cotopaxi Limited,
Vulcanic and Durex Industries, our reported financial results for
2022 only include the impact of these operations for the period of
ownership by the Group. The table below reconciles between
statutory revenue as reported within the Consolidated Income
Statement, and the 2022 proforma revenue had all acquisition and
disposal transactions occurred on 1st January 2022. This
allows users of the accounts to compare 2023 revenue to 2022
revenue on a like-for-like basis.
|
Revenue
(statutory)
£m
|
Proforma
adjustments1
£m
|
Revenue
(proforma)
£m
|
Proportion of
Group
|
Steam Thermal Solutions
|
866.0
|
(1.2)
|
864.8
|
50%
|
Electric Thermal
Solutions
|
256.1
|
126.8
|
382.9
|
22%
|
Watson-Marlow
|
488.5
|
(1.9)
|
486.6
|
28%
|
Total
|
1,610.6
|
123.7
|
1,734.3
|
|
1includes the 2022 pre-acquisition
financial results of Cotopaxi Limited, Vulcanic and Durex
Industries, and the removal of the 2022 statutory
results of our Russian operating
companies disposed
Analysis by operating segment
2023
|
Revenue
£m
|
Adjusted
operating
profit
£m
|
Adjusted
operating
profit
margin
%
|
Steam Thermal Solutions
|
910.1
|
224.0
|
24.6%
|
Electric Thermal
Solutions
|
378.5
|
59.2
|
15.6%
|
Watson-Marlow
|
394.0
|
93.7
|
23.8%
|
Corporate
|
-
|
(27.8)
|
|
Total
|
1,682.6
|
349.1
|
20.7%
|
|
|
|
|
Net finance expense
|
|
(39.9)
|
|
Share of (loss)/profit of
associate
|
|
-
|
|
Adjusted profit before taxation
|
|
309.2
|
|
|
|
|
|
|
|
|
|
2022
|
Revenue
£m
|
Adjusted
operating
profit
£m
|
Adjusted
operating
profit
margin
%
|
Steam Thermal Solutions
|
866.0
|
206.1
|
23.8%
|
Electric Thermal
Solutions
|
256.1
|
39.9
|
15.6%
|
Watson-Marlow
|
488.5
|
160.0
|
32.8%
|
Corporate
|
|
(25.8)
|
|
Total
|
1,610.6
|
380.2
|
23.6%
|
|
|
|
|
Net finance expense
|
|
(9.6)
|
|
Share of (loss)/profit of
Associate
|
|
-
|
|
Adjusted profit before taxation
|
|
370.6
|
|
The reconciliation for each
operating segment for adjusting items is analysed below:
2023
|
Amortisation
of acquired
intangibles £m
|
Reversal of fair value
adjustments to inventory
£m
|
Restructuring
costs
£m
|
Acquisition-related
items
£m
|
Disposal of
associate
£m
|
Impairments
£m
|
Total£m
|
Steam Thermal Solutions
|
(4.5)
|
-
|
-
|
(0.4)
|
-
|
(13.9)
|
(18.8)
|
Electric Thermal
Solutions
|
(29.5)
|
(1.3)
|
2.3
|
(4.9)
|
-
|
-
|
(33.4)
|
Watson-Marlow
|
(3.2)
|
-
|
(7.5)
|
-
|
-
|
(1.8)
|
(12.5)
|
Corporate expenses
|
-
|
-
|
-
|
(0.4)
|
0.4
|
-
|
-
|
Total
|
(37.2)
|
(1.3)
|
(5.2)
|
(5.7)
|
0.4
|
(15.7)
|
(64.7)
|
2022
|
Amortisation
of acquired
intangibles
£m
|
Reversal of fair value
adjustments to inventory
£m
|
Disposal of subsidiaries in
Russia
£m
|
Restructuring
costs
£m
|
Acquisition-related
items
£m
|
Accelerated depreciation and
other related costs on one-off property
redevelopment
£m
|
Total
£m
|
Steam Thermal Solutions
|
(4.6)
|
-
|
(5.3)
|
-
|
-
|
-
|
(9.9)
|
Electric Thermal
Solutions
|
(15.3)
|
(1.8)
|
-
|
(15.5)
|
-
|
-
|
(32.6)
|
Watson-Marlow
|
(3.8)
|
-
|
(1.8)
|
-
|
-
|
-
|
(5.6)
|
Corporate expenses
|
-
|
-
|
-
|
-
|
(9.1)
|
(4.2)
|
(13.3)
|
Total
|
(23.7)
|
(1.8)
|
(7.1)
|
(15.5)
|
(9.1)
|
(4.2)
|
(61.4)
|
|
|
|
|
|
|
|
|
| |